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Abstract— Plasma, the fourth and most pervasive state of matter 
in the visible universe, is a fascinating medium that is connected to 
the beginning of our universe itself. Man-made plasmas are at the 
core of many technological advances that include the fabrication 
of semiconductor devices, which enabled the modern computer 
and communication revolutions. The introduction of low 
temperature, atmospheric pressure plasmas to the biomedical 
field has ushered a new revolution in the healthcare arena that 
promises to introduce plasma-based therapies to combat some 
thorny and long-standing medical challenges. This paper presents 
an overview of where research is at today and discusses innovative 
concepts and approaches to overcome present challenges and take 
the field to the next level. It is written by a team of experts who 
took an in-depth look at the various biomedical applications, made 
critical analysis, and proposed ideas and concepts that should help 
the research community focus their efforts on clear and practical 
steps necessary to keep the field advancing for decades to come.   
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I. INTRODUCTION 
M. Laroussi, A. Bogaerts, and XP Lu 
 
The multidisciplinary field of the biomedical applications of 
atmospheric pressure low temperature plasma (AP-LTP) has 
been 25 years in the making [1 - 12]. Since its introduction in 
the mid-1990s the field has expanded tremendously and has 
reached several critical and very important milestones, which 
include clinical trials on wound healing and cancer treatment. 
These advancements and successes have been accomplished 
thanks to the outstanding contributions of many investigators 
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and research groups from around the world. A quarter century 
may seem like a long time for an individual investigator but for 
a typical field of science it is a relatively short period of time. 
Yet, the advances and accumulation of new knowledge about 
the interaction of plasma with living soft matter has been 
nothing short of impressive. Today, our scientific knowledge 
concerning the physical and biochemical pathways involved in 
the interaction of plasma with biological cells and tissues has 
reached a good level of maturity. However, more remains to be 
done both on the fundamental and application levels. So, 25 
years seems like a good time marker for the research 
community to take a good look and evaluate the current state of 
the field, identify the challenges and obstacles, and propose 
ideas on how these could be overcome. These are the main 
objectives of this roadmap paper. A team of experts in the 
various sub-topics of the field has been tasked to each 
summarize the present status of their sub-topic, inform the 
research community about the remaining challenges, and 
propose potential approaches and methods that can be 
employed to overcome these challenges.  
LTP produces a rich “cocktail” of reactive species including 
reactive oxygen species, ROS, and reactive nitrogen species, 
RNS, which have been shown to play pivotal roles in the 
observed biomedical outcomes [13]. LTP sources also exhibit 
high electric fields and produce photons at various 
wavelengths/energies, which can also play synergistic 
biological roles. The state of knowledge regarding the effects 
of these plasma-produced agents is quite advanced as of the 
present, but many of the effects on the subcellular and 
molecular levels are either not fully understood or a matter of 
debate. To help elucidate these effects, advanced modeling and 
simulation approaches have been brought to bear on many of 
these issues [14] – [17].  In addition, in the aim of making LTP 
biological effects reproducible under similar operating 
conditions, it is important to develop control methods that allow 
for the minimization of the effects of environmental conditions, 
such as humidity, temperature, air pressure (e.g., altitude), 
power fluctuations, etc. while at the same time optimizing the 
treatment as a function of the properties of the target (shape, 
surface morphology, thickness/depth, conductivity, etc.). These 
are some of the outstanding issues that are discussed in this 
paper. Ideas and new concepts to tackle these challenges are 
proposed, providing an outlook on what still needs to be done 
and where the field is headed in the near future. 
The paper is organized in seven sections. The first section 
discusses low temperature plasma sources. The application of 
plasma in biology and medicine would not have been possible 
without the development of atmospheric pressure low 
temperature plasma sources. However, there are still 
outstanding issues, such as control of these sources to achieve 
optimal performance for any application they are used for. The 
second section discusses the application of LTP in biological 
decontamination. This was the first bio-application of LTP and 
the initial seed that was at the genesis of the entire field. This 
application has proved to be of the utmost importance, because 
of the advent of antibiotic resistance of bacteria and pathogenic 
proteins (such as prions), and because of viral-driven 
pandemics, such as the present COVID-19 pandemic. The third 
section discusses the use of LTP to treat water and air. Plasma 
treatment of water is used for nitrogen fixation, reduction of 
pollutants, and inactivation of pathogens in the food cycle, food 
safety, and for water purification. For air treatment, 
traditionally plasma has been used for the inactivation of 
airborne pathogens. For example, HVAC systems can be 
retrofitted with a plasma treatment stage to purify indoor air 
from biological contaminants. However, with the advent of 
viral-driven pandemics (such as COVID-19), plasma treatment 
of air has taken a renewed importance. The fourth section 
discusses LTP-assisted wound healing. This was the first 
patient-centered medical application of LTP and maybe one of 
the most developed and has undergone extensive animal studies 
followed by clinical trials at various hospitals, especially in 
Germany. One of the therapeutic challenges is the healing of 
chronic wounds. Chronic wounds, such as diabetic ulcers, do 
not heal easily or at all. Thousands of amputations occur every 
year in the US alone, because of the inability of conventional 
methods to satisfactorily deal with this problem. LTP has been 
shown to safely coagulate blood and enhance the proliferation 
of cells such as fibroblasts, which made gas plasma an attractive 
technology for wound healing. The fifth section deals with the 
application of LTP in the field of dentistry. Here LTP has been 
used in three areas of dentistry: periodontal, endodontic and 
prosthodontic treatments. LTP has also been used “indirectly” 
for surface modifications of implants, oral surgery to improve 
interfacial bonding strength of dental objects used in 
periodontics or prosthodontics, and sterilization of dental 
instruments. The sixth section discusses cancer treatment by 
LTP, what is referred to as “plasma oncology”. This application 
has seen great progress in the last decade that recently 
culminated in preliminary clinical trials in a few hospitals in 
Germany and the USA. In vitro Investigations have shown that 
LTP can kill cancer cells and In vivo experiments have shown 
that LTP treatment can shrink tumors size and/or delay their 
growth. However, there is still much work to be done to 
understand the effects of LTP on cancer cells on the sub-cellular 
and molecular levels and the effects on the tissues surrounding 
tumors. Finally, the seventh section of this paper discusses 
modeling and simulation works that have been conducted so far 
to further elucidate the plasma-cell and plasma-tissue 
interactions. The interaction of LTP with entire cells or tissue 
can up to now only be simulated on a macroscopic scale, 
obviously providing less detailed information than modeling 
the interactions with individual cell components, such as the 
phospholipid bilayer, DNA or proteins, which is possible on the 
molecular level. Much progress has been made in recent years, 
but more work has to be done, and major challenges are the 
compromise between calculation time and level of detail of the 
simulations, the need for accurate input data and experimental 
validation, and the translation of the obtained insights towards 
improving the biomedical applications. 
To conclude, research on the biomedical applications of low 
temperature plasma has, first of all, produced new, previously 
missing, fundamental scientific knowledge regarding the 
interaction of the fourth state of matter with soft biological 
matter. Second, LTP is proving to be a technology that can help 
meet many of today’s healthcare challenges, including the 
inactivation of antibiotic-resistant bacteria, the healing of 
chronic wounds, treatment of various dermatological diseases, 
and even some types of cancers. More recently, agricultural 
applications have also emerged, which include 




treatment/decontamination of fruits and legumes for longer 
shelf life, the modification of the wettability of the surfaces of 
seeds, and the enhancement of the germination speed and yield 
of plant seeds. Finally, LTP may also be a viable technology for 
space medicine. Here plasma can replace perishable medication 
and can be used to decontaminate tools and gear from possible 
extraterrestrial microorganisms and to disinfect wounds and/or 
skin infections that astronauts may experience during long-
duration space missions. To ensure that LTP technology can 
meet all the requirements of effectiveness and safety for the 
above listed applications, the research community needs to 
identify all the remaining scientific and technical challenges 
and seek creative solutions that can take the field to the next 
level. We hope that this paper plays a role in this endeavor and 
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II. LOW TEMPERATURE PLASMA SOURCES 
S. Reuter, A. Mesbah, D. Liu, X. Lu, M. Laroussi, and K. 
Ostrikov 
II.1 Current state 
plasma sources: 
Two main types of low temperature plasma (LTP) sources 
have been used in plasma medicine research, dielectric barrier 
discharges (DBDs) and non-equilibrium atmospheric pressure 
plasma jets (N-APPJs) [1], of which many varieties exist. N-
APPJs quickly became widely applied LTP sources because 
they can generate a stable and controllable plasma volume 
outside the confinement area of electrodes within the 
surrounding environment [2]. This is crucial for a direct plasma 
treatment of diseased tissue on a patient [3]. Biologic effects of 
LTP sources in medicine include sterilization/decontamination 
of biotic and abiotic surfaces, the promotion of growth factors, 
control of cell migration, induction of apoptosis, angiogenesis, 
microcirculation and modulation of the immune response [4] – 
[6]. These effects have been attributed to the reactive oxygen 
and nitrogen species (RONS), electric field, charged particles 
and ultraviolet radiation (UVR) generated by LTP [7 - 9]. 
Because LTP can help preventing the aerosol transmission of 
respiratory infectious diseases such as tuberculosis and the 
Coronavirus disease 2019 (COVID-19) [10, 11-13], recent 
research focus was set on plasma sources for reduction of 
pathogenic biological aerosols (PBAs). 
A second classification of biomedical LTPs is application 
mode oriented – two key types are distinguished: direct and 
indirect plasma sources [10]. For the first type, the plasma has 
direct contact to the treated surface, the second type does not. 
In the case of direct LTP sources, the treatment target (skin, 
wound, tissue, etc.) acts as the counter electrode, therefore the 
discharge current (displacement or conduction current) flows 
through the body. One example of direct LTP sources is shown 
in Figure II.1 (a) [4,14]. A typical plasma jet is shown in Figure 
II.1 (b). A pin electrode covered by a dielectric tube with one 
end closed is the power electrode [15] while the ring electrode 
outside the tube is the ground electrode [16]. A commercial 
version of this type of N-APPJ is the kINPen [17]. More 
configurations of plasma jets can be found e.g., in [2] and [15]. 
For indirect LTP sources, the plasma is mainly produced 
between the electrodes and some reactive species of the plasma 
can reach the surface of the target via the electric field 
propagation (ionization wave), convection and diffusion 
mechanisms [15]. An air DBD-based indirect LTP source is 
shown in Figure II.1 (c) [18]. A commercial version of this type 
of LTP is the PlasmaDerm device. Convection through the air 
flow delivers RONS generated by the plasma inside the tube to 
the treatment target. Another indirect LTP, the surface 
dielectric barrier discharge (SDBD) shown in Figure II.1 (d) A 
thin plasma layer forms between the grounded electrodes’ 
structures. The reactive species and UV light can interact with 
the object surface due to the short distance between the 
grounded electrode and the target’s surface [5].  
Recently, air plasma sources which can generate stable air 
discharges under conditions of high air flow rate have been used 
to sterilize PBAs. Figure II.1 (e) shows the structure of 
bioaerosol disinfector based on an atmospheric-pressure 




positive corona discharge. Another example of DBD plasmas 
in air that can inactivate aerosolized Bacillus subtilis cells and 
Pseudomonas fluorescens indoor and outdoor is shown in 
Figure II.1 (f). [19, 20]. It is important to note that the large 
plasma volume covers almost the entire cross section of the 
quartz tube, largely increasing the interaction intensity between 
the plasma and PBAs. 
 
Fig. II.1 Schematics of low temperature plasma (LTP) 
sources. Direct LTP sources: (a) The volume-air dielectric 
barrier discharges (DBDs) with a gas gap in the mm range. (b) 
Typical DBD plasma jets. Indirect LTP sources: (c) Air DBD 
was generated inside the ceramic tube. (d) Surface air DBDs. 
LTP sources inactivating bioaerosols: (e) The needle corona 
discharge array to inactivate Penicillium aerosols. (f) The air 
DBD system (quartz tube) to kill airborne bacteria or virus. 
 
Plasma Processes: 
In the past decade, enormous progress has been made in the 
characterization of atmospheric pressure LTP sources. This can 
be attributed to the technology development of diagnostics, as 
well as to a deeper knowledge of plasma chemistry and 
processes through the combination of modelling and 
diagnostics. Through reference plasma sources [21] and a 
continuing development of high-precision diagnostic methods 
for absorption spectroscopy [22], emission and laser 
spectroscopy [23], and non-optical methods such as mass 
spectrometry [24], a thorough understanding of the plasmas has 
been achieved [9, 23, 25, 26].  
Most recent developments to understand plasma processes 
focus on electric fields in plasmas, electron properties and 
energy dissipation pathways [27]. The emergence of ultrafast 
diagnostic techniques has enabled researchers to observe the 
generation of reactive species and space resolved electric field 
dynamics in plasma breakdown relevant time scales [28]. 
Finally, especially for the medical field, the interaction and 
transport processes of the plasma generated reactive species 
into liquid environments are fundamental [29]. Substantial 
progress has been made in the ability to control plasma 
activated solutions and using mixed-phase systems such as 
plasma-bubble systems to enhance the reactivity and other 
relevant physical and chemical progress. These advances have 
been made through the close interaction of physicists, engineers 
and chemists.  
 
Plasma Control: 
Control over plasma composition is mandatory for a targeted 
medical application. Tremendous progress has been made in 
controlling electron dynamics e.g., through a multi-frequency 
approach [30]. Ensuring a reproducible composition by using a 
tailored gas surrounding the active effluent has opened the door 
to several promising fundamental biomedical studies. 
Traditionally, control of LTPs has primarily relied on statistical 
process control strategies, as widely used in semiconductor 
manufacturing. However, such control strategies are inherently 
open-loop, in which the lack of on-line sensing and feedback 
corrective action can compromise the reliability and 
repeatability of LTPs due to the intrinsic plasma variabilities 
and external disturbances. The key challenges in feedback 
control of LTPs stem from 1) the nonlinear interactions between 
multiple input variables (i.e., discharge parameters) and 
multiple output variables of a plasma discharge (i.e., plasma 
effects), 2) the need to constrain the plasma properties to ensure 
safe plasma treatment and circumvent adverse plasma-induced 
surface effects, and 3) the need to realize the proper synergy 
between the chemical, physical, and electrical effects of LTPs 
when interacting with complex biological surfaces [31]. 
Recently predictive control and learning-based control 
approaches have shown exceptional promise for safe, effective 
and reproducible operation of N-APPJs [32,33,34]. Reduced-
order, physics-based models and data-driven models have been 
used to develop model predictive control (MPC) strategies for 
constrained, multivariable control of the nonlinear effects of 
plasma on surfaces [32,35]. Experimental studies using cell and 
chemical assays have correlated operational parameters of 
CAPs such that real-time monitoring of the plasma’s chemical 
effects can be effectively utilized in an adaptive manner for 
feedback control [36]. These studies have been extended to 
develop MPC-based strategies for targeted cancer cell treatment 
using real-time electro-chemical impedance spectroscopy 
measurements [37]. Furthermore, deep neural network-based 
controllers have been demonstrated to be particularly useful for 
control of N-APPJs using resource-limited embedded systems, 
which are especially suitable for portable and point-of-use 
biomedical applications [38]. 
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Despite the fact that many LTP sources suitable for 
biomedical applications have been developed and successfully 
applied in vitro and in vivo, the number of clinical trials remains 
relatively small [39]. One of the crucial challenges relates to the 
controlled delivery of plasma agents to diseased targets. The 
challenges are similar to those of plasma processes in the 
semiconductor industry in the 1990s that arose due to the 
significant lack of knowledge about the fundamental 
mechanisms involved in the plasma-materials interactions. A 
concerted R&D effort in academia and industry allowed the 
identification of the plasma parameters and substrate properties 
and geometries that led to the desired manufacturing process. 
Dry etching by plasma thus became commonplace technology 
in semiconductor production. The plasma medicine community 
is currently at a similar development stage with lessons to be 
learned from the semiconductor processing experience which 
necessitated substantial numerical modelling assisted process 
analysis [40 - 42].  
A stark difference between the technological and the medical 
application of LTPs is the certification procedures of medical 
plasma sources. While more and more plasmas are used in 
medical research and some countries have certified plasma 
sources for medical use, a clear path to bringing a new type of 
plasma source to clinical application remains to be found. 
Although more progress in the field of new LTP sources and 
innovative biological applications are desirable, there are 
fundamentals issues that still need to be addressed. These can 
be subdivided into the three areas Plasma physics and 
chemistry, biomedicine, and LTP technology development. The 
following questions require further investigations to be able to 
reach a knowledge-based plasma medicine approach: 
 
Plasma physics and chemistry: 
How do electric field dynamics in N-APPJs lead to the 
generation of energetic electrons, ions and reactive oxygen and 
nitrogen species? What is the role of rotational-vibrational-
translational energy transfer? How can the concentrations and 
fluxes of RONS be accurately controlled? How can plasma 
induced reactivity be delivered through different media without 
undue influence of environmental factors?  
Biomedicine: 
What are the effects of treatment target properties and 
composition (skin, the wound covered by effusion, tumors, 
aerosols, etc.) on LTP characteristics? How do we standardize 
the flux and energy of LTP transmitted to cells and tissues to 
appropriately define “plasma dose”?  
 
LTP technology development: 
How can we use artificial intelligence (AI), new materials, 
and new power electronics technology to optimize the design of 
the LTP sources and control the plasma? How do we ensure that 
LTP biomedical applications are patient compatible? How can 
LTP technology be designed sustainably to enable end-of-life 
re-cycling and re-use of the electrodes, electronic components 
and other parts of the plasma devices? How can plasma sources 
be adapted to the respective treatment requirements and be 




LTP sources development is an interdisciplinary research 
area, therefore, collaborations between plasma physics and 
chemistry, power electronics, fluid dynamics, microbiology 
and medical science are required (Figure II.2). In order to set up 
the roadmap for applied physics here, we concentrate on the 
challenges in the three areas mentioned above.  
 
Fig. II.2 Three key areas affecting the development of LTP 
sources – 1) plasma physics and chemistry 2) Biomedicine and 
3) LTP technology development. The collaboration of 
multidisciplinary scientific community will enhance the 
understanding of fundamental mechanisms of operation of LTP 
sources. Feedback loops between the key areas include reactive 
species generation and delivery, protocols and adapted 
protocols as well as the equivalent total oxidation potential 
(ETOP). 
 
It is necessary to carry out experimental and simulation work 
to thoroughly elucidate and determine all the physical and 
chemical processes in a cohesive way. For example, in the case 
of N-APPJs, using fast imagery with high spatial resolution (μm 
range) and high time resolution (sub-ns range) along with 2D 
or 3D simulation models, the effect of photo-ionization, seed 
electrons and electric field can be obtained.  
To understand where and how the active constituents 
generated by the plasma, reactive oxygen and nitrogen species 
(RONS), UV, charged particles, and electric fields are 
generated, their interactions, and interdependence is important. 
Measurement techniques such as infrared absorption 
spectroscopy for radical and molecule detection, optical 
emission spectroscopy for discharge dynamics, Stark 
spectroscopy or electric field induced second harmonic 
generation for electric field, Thomson, Raman and Rayleigh 
scattering for electron parameters, laser induced fluorescence 
(LIF) for radical and molecules detection, and mass 
spectrometry can be employed. 2D or 3D simulations with 
hundreds of plasma reactions will facilitate the identification of 
the main production mechanisms of the plasma reactive species 
(see chapter on modelling). 
When LTP sources are used to treat fluid-covered wounds or 
bioaerosols, plasma comes in contact with liquids. Therefore, 
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understanding of the discharge processes happening at the gas–
liquid interface. The evaporation of liquid is an important 
process, because it not only affects the plasma chemistry, but 
also decreases the lifetime of bioaerosols. On the other hand, 
when LTP is used to treat skin diseases such as psoriasis, the 
scurf or accretive tissue may decrease the delivery of plasma, 
making it necessary to adjust the plasma treatment dose. 
Since the reactive components of the plasma  consist of a 
large variety of species it is difficult to standardize plasma 
treatments. A proposed metric is the equivalent total oxidation 
potential (ETOP) (See Figure 2) which includes all RONS and 
UV/VUV generated by the plasma, could be used to evaluate 
the plasma dose [43]. If the ETOP of a plasma source is known 
at different values of power, temperature and humidity, this 
could facilitate the expansion and application of LTP 
technology in medicine. 
Plasma source development ranges from small to large scale 
devices and the design is driven by the target application. In any 
case, moving towards mobile and personalized devices will 
greatly enhance application fields to include ambulant, point of 
care or even in a home care environment. Battery powered 
devices or low power devices are promoting this development 
(e.g. [44]).   
The rapid development of artificial intelligence (AI) can be 
used to transform the mathematical modeling, real-time 
diagnostics, and optimal operation of LTP sources for 
applications in plasma medicine [45]. In addition, new 
oxidation-resistant and high-strength electrode materials as 
well as new power semiconductor devices can enhance the 
efficiency of LTP sources and reduce the cost of their 
development and manufacturing. Environmental considerations 
should be taken into consideration to reduce emissions of 
harmful gases and meet personnel minimum exposure 
requirements of gases such as ozone.  
Finally, the certification issues need to be addressed. The 
market is steadily growing for plasma medicine, but a 
standardized certification procedure is still missing, while first 
attempts have been made for a minimal characterization 
requirement [46]. Lacking certification procedures could 
ultimately pose a great risk to the field, due to insufficiently safe 
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III. LTP FOR BIOLOGICAL DECONTAMINATION  
 
J. Walsh, M. Laroussi, M. Keidar, and C. Laux 
III.1 Current State 
The use of low-temperature plasma for the decontamination 
of biological agents has been under intensive investigation for 
several decades. Commercial LTP decontamination systems, 
employing low-pressure plasma, are nowadays widely used in 
healthcare settings across the world for the sterilization of 
temperature sensitive medical devices. While low pressure LTP 
systems are undoubtedly efficient for biological 
decontamination, the added cost and complexity of a vacuum 
based process limits their broader appeal. At the end of the 
twentieth century, interest in the use of plasma for biological 
decontamination was reignited with a demonstration that LTP 
generated under ambient pressure conditions could be 
harnessed for the non-thermal inactivation of microorganisms 
[1]. Much of this early work focused on the use of noble gas 
plasma jets due to their ease of use and convenience [2], with 
more efficient and inevitably more complex LTP-based 
decontamination devices being developed over the subsequent 
years to meet a growing number of application needs.  
As the area of research continues to expand, it is becoming 
more diverse and varied. While early works focused primarily 
on the use of LTP to eliminate planktonic bacteria, recent 
efforts have focused on more representative contamination such 
as antibiotic resistant bacteria [3], mixed species biofilms [4], 
and endospores [5]; conditions that present a formidable 
challenge to any non-thermal decontamination technology. 
Beyond bacterial contamination, the global SARS-CoV-2 
pandemic has placed a spotlight firmly on the need to develop 
fast, efficient and low-cost viral decontamination techniques 
that can be easily deployed beyond a healthcare setting. Given 
the minimal equipment costs and the possibility of consumable-
free operation of LTP, many members of the plasma science 
community have turned their attention to viral decontamination. 
These efforts have resulted in a number of published studies 
within the past 12 months that comprehensively demonstrate 
the efficiency of LTP against viral agents [6], [7], a clear 
indication that the plasma science community is both flexible 
to adapt and willing to tackle some of the greatest challenges 
facing humanity. 
 
III.2 Challenges and Proposed Solutions 
 Current and Future Challenges 
Underpinning the use of LTP for biological decontamination 
is the multiphase interaction between a non-equilibrium gas 
plasma and a target organism; given the shear complexity of 
this interaction a plethora of scientific challenges remain 
unresolved. These challenges essentially fall into distinct areas, 
such as the need to understand and control fundamental LTP 
processes, and the need to understand the biological effects of 
LTP exposure at the target, Figure III.1. Adding to the 
complexity is the two-way interaction between the LTP and its 
target, often giving rise to emergent and synergistic behaviors 
that are difficult to predict, characterize and control.  






Fig.III.1 Diagram showing the priority decontamination 
targets for LTP and challenges relating to the understanding 
and control of LTP for effective, efficient, and repeatable 
biological decontamination. 
 
Perhaps one of the greatest contemporary challenges 
associated with LTP mediated decontamination relates to 
unravelling the underpinning mode of action that determines 
the efficacy of the process; a challenge that is further 
exasperated by the large number of different plasma systems 
currently under investigation, with each system presenting 
different operating characteristics and parameters, combined 
with the vast number of biological agents being explored [5]. 
Great progress has been made in this area over the past decade, 
with increasingly sophisticated techniques being adopted to 
gain new levels of insight. Despite this progress, more needs to 
be done, especially at the biomolecular level. Critically, 
understanding the mode of action is only the first step in 
developing an effective LTP decontamination system. Being 
able to manipulate and control the fundamental LTP processes 
to elicit a desired biological response at the target remains the 
‘holy grail’ in the area, yet such control extends beyond our 
current capabilities. A key advantage of LTP technology is its 
ability to be applied directly at the point of need, in many 
situations this is likely to be beyond the laboratory in an 
environment that is in a constant state of flux. Given that much 
of the reactivity of an LTP system can be derived from its 
interactions with the surrounding environment, be it from air 
entrainment within a plasma jet plume [8], or through the direct 
generation of LTP in ambient air [9], the question of how to 
generate a consistent discharge composition in a constantly 
changing environment remains unresolved.  
While understanding and controlling LTP processes is the 
key to ensure efficiency and repeatability of the 
decontamination processes, many challenges relating to the 
underpinning biomolecular processes must also be addressed. 
Typically, these challenges are highly specific to the biological 
target: 
Bacteria and biofilm formation:  
In the natural environment, microorganisms cluster together 
and form a protective layer as a means of self-preservation, this 
community is known as a biofilm. Typically, microorganisms 
encased within a biofilm are 1000 times more resistant to 
antimicrobial agents than their planktonic counterparts. When 
LTP interacts with a biofilm the antimicrobial agents created 
must first penetrate this protective layer, known as the 
Extracellular Polymeric Substances (EPS). The complex 
composition of the EPS acts to inhibits the transport of reactive 
agents to the encased microorganisms, significantly 
diminishing decontamination efficacy. Biofilms also present 
ideal conditions for the formation of antimicrobial resistance, 
one of the greatest challenges facing humanity in the 21st 
century. Indeed, the key questions of if, how and how quickly 
microorganisms form resistance to LTP remain unanswered. 
Viruses:  
The use of LTP to decontaminate viruses has been under 
active investigation for several years, yet it was not until the 
emergence of SARS-CoV-2 and the subsequent pandemic that 
the approach gained mainstream attention. Recent approaches 
have demonstrated effective LTP mediated surface and airborne 
SARS-CoV-2 decontamination [7]. More now needs to be done 
to understand the underpinning mode of antiviral action and 
demonstrate efficacy and repeatability. Compounding this 
challenge is our ability to test LTP systems under real-world 
conditions; SARS-CoV-2, like many other viruses of concern, 
are highly infectious and any scientific study must be conducted 
in a laboratory with an appropriate containment level. Many 
researchers do not have access to such facilities and have 
therefore adopted surrogate models, such as the use of 
bacteriophages and pseudoviruses [10], [11]. Despite extremely 
promising results, the applicability of these models remains 
unclear, and more work is needed to understand how the model 
results translate to real-world efficacy. Another challenge in 
thus area relates to how best to apply LTP, with it potentially 
being used to remove airborne viruses that are in an aerosolized 
form or applied directly to decontaminate surfaces.  
Infectious proteins:  
Prions are misfolded proteins with the ability to transmit their 
misfolded shape onto normal variants of the same protein. Prion 
diseases are a family of rare progressive neurodegenerative 
disorders that affect both humans and animals. Typically, prion 
contaminated materials are extremely difficult to 
decontaminate, with reports indicating prions remain infective 
following incineration at 600oC [12]. Consequently, prions 
present a formidable challenge for LTP decontamination yet 
numerous studies have reported promising results [13]. Several 
challenges are yet to be resolved in this promising area, perhaps 
the most important of which relates to the underpinning mode 
of action and impact of LTP exposure on the protein structure 
and conformation. Another key issue that is yet to be fully 
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addressed relates to the fate of the exposed prions, are they 
completely eradicated or are they simply dislodged from the 
surface by LTP and transported elsewhere?  
 
Proposed Solutions 
The LTP community has an ever-growing arsenal of 
sophisticated diagnostics techniques at their disposal; methods 
such as Laser Thomson Scattering (LTS) and femtosecond 
Two-photon Laser Induced Fluorescence (fs-TALIF) are 
becoming more widespread and can provide an unprecedented 
level of insight into fundamental plasma processes [14], [15]. 
Despite this progress, the shear level of complexity and 
multiscale nature of plasma-bio interactions dictates that 
experimental techniques alone will not be sufficient to uncover 
a full understanding; computational modelling therefore has a 
major role to play. While computational plasma models are 
becoming increasingly advanced and provide a deeper level of 
insight than ever before [16], the introduction of a realistic 
biological entity into such models extends beyond our current 
ability. To overcome this formidable challenge, a fusion of 
different modelling techniques will be essential, with 
approaches such as those used in molecular dynamics being 
integrated within conventional LTP modelling codes to provide 
a new insight at the biomolecular level. 
In addition to our increasing knowledge of LTP processes, 
more insight into the biomolecular processes induced by LTP 
exposure is essential to guide process optimisation and instil 
confidence in potential end-users. In terms of virus inactivation, 
understanding the impact of LTP generated components on 
viral DNA/RNA alongside proteins and membranes is essential. 
Techniques such as RNA/DNA sequencing should be adopted 
to characterise the viral genome, monitor viral gene expression 
and genome replication in response to LTP exposure. While the 
efficiency of LTP mediated virus inactivation should be 
assessed on appropriate cell lines using different standardised 
methods, such as the plaque assay and the 
immunohistochemical focus forming assay [17]. To further 
enhance our knowledge of LTP mediated biofilm denomination 
genomic, proteomic and metabolomic studies are vital to obtain 
a quantitative understanding of the spatial and temporal 
variation in the microenvironment of cells embedded within the 
biofilm EPS and how LTP-introduced agents affect cell-cell 
communication. Antimicrobial resistance remains a key 
challenge for any novel decontamination technology and the 
impact of LTP exposure on the emergence of resistance and 
adaptation of microorganisms remains unclear; addressing this 
will require dedicated genotypic approaches such as PCR and 
DNA hybridization methods. Finally, LTP interaction with 
infectious proteins requires a detailed investigation into 
possible changes to the protein structure and conformation, 
using both classical techniques such as X-ray crystallography 
and Nuclear Magnetic Resonance (NMR), coupled with 
emerging techniques such as cryo-electron microscopy (cryo-
EM) [18]. 
Armed with a clear understanding of the fundamental 
processes at play the question of LTP manipulation and control 
must be addressed. Given that it is desirable to operate LTP 
under ambient pressure conditions, the resulting plasma is 
highly collisional hence many of the techniques successfully 
developed to control low-pressure plasma are ineffective. 
Advanced power sources employing dual frequency excitation 
or short voltage pulses (nanosecond and sub-nanosecond 
duration) may offer the exciting ability to manipulate the 
electron energy distribution function high-pressure LTP and 
therefore provide a means to manipulate RONS generation. 
While such techniques are promising, knowing how to control 
LTP processes is only one part of the puzzle, knowing how to 
control them to achieve the desired biological response in an 
ever-changing environment is the ultimate key to successes. 
Addressing this challenge will undoubtedly require a closed-
loop control methodology, informed by real-time sensing and 
diagnostics. Very few LTP systems currently under 
investigation employ feedback and are thus highly susceptible 
to fluctuations in the external environment, ultimately 
impacting their efficiency and repeatability [19], [20]. To 
support the development of real-time and closed loop control 
systems many lessons can be drawn from the field of data 
science, machine learning and artificial intelligence. Exciting 
preliminary results have demonstrated that predictive control 
methodologies can be applied to harness LTP [21], with such 
strategies facilitating the control of a complex black-box 
function, such as an LTP interacting with a biological target, 
with little prior knowledge of the systems characteristics. 
To conclude, as the development of LTP technology for 
biological decontamination spans the field of plasma science, 
engineering, and the life sciences; consequently, a 
multidisciplinary approach is therefore essential to make 
progress. While the LTP community has been extremely 
successful in demonstrating the potential of the technology for 
biological decontamination in a plethora of exciting application 
areas, further engagement with scientists from beyond the LTP 
domain is essential to overcome the formidable research 
challenges that remain. As with other LTP applications in the 
biomedical field, a key challenge is understanding the complex 
underpinning mechanisms of plasma action, an endeavour that 
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IV. PLASMA TREATED AIR AND PLASMA TREATED WATER 
K. Stapelmann, S. Mededovic Thagard, and A. Fridman 
 
IV.1 Current state 
The growing use of atmospheric pressure plasma opened the 
door for their applications in the treatment of water and air. 
During the last decade, plasma treatment of water has been 
investigated for nitrogen fixation, reduction of pollutants, and 
inactivation of pathogens in the food cycle, food safety, and 
water purification arenas. The treatment of air, which 
traditionally has been focused on the inactivation of airborne 
pathogens in air flows and on their chemical cleaning, has 
gained significant renewed interest due to the COVID-19 
pandemic 
 
Plasma treated water for the food cycle and food safety: 
Low-temperature plasma (LTP) science and technology has 
found its place in agriculture for applications ranging from 
sustainable fertilizer production to food safety and reduction of 
pollution and pathogens. Sustainable farming is an international 
priority due to world population growth, global warming and 
decreases in arable land. Sustainable farming requires efficient 
management of water and nitrogen-based fertilizers to conserve 
scarce water resources, minimize environmental impact and 
reduce fossil-fuels now used for fertilizer production, mainly 
with the Haber-Bosch process. To supplement the global 
nitrogen demand and offer environmental protection a more 
flexible process can be developed with plasma-treated water 
(PTW), see Figure IV.1 for an example PTW reactor. PTW has 
been used for the irrigation of seeds and seedlings, showing a 
growth-promoting effect.  This opens up the possibility of 
precisely manipulating plant productivity while enhancing 
plant resilience to biotic and abiotic stresses [1]. PTW for 
fertigation (fertigation is injection of fertilizers and chemicals 
into an irrigation system) of plants can be used to supplement 
nitrogen in soil and soilless systems, as well as to control pH 
and bacterial load in recirculating nutrient solutions in soilless 
systems. In case of seed irrigation with PTW, the seeds are 
exposed to hydrogen peroxide (H2O2) and nitric oxides (NOx), 
which may trigger changes in plant hormones, promoting 
germination. LTP offers the unique opportunity to tailor and 
control reactive species produced. 
 
 
Fig. IV. 1 A dielectric barrier discharge for nitrogen fixation in 
water. The plasma is in direct contact with the water surface. 
To increase the residence time and the surface area to volume 
ratio, air is flown through the plasma and bubbled into a 500 ml 
water column. (courtesy of Plasma for Life Sciences 
Laboratory, North Carolina State University). 
 
Addressing another grand challenge, the reduction of post-
harvest loss, PTW has been applied to fresh produce to reduce 
microorganisms and potential chemical contaminants on food 
[2]. It is well known that plasma and PTW have antimicrobial 
effects [3–5] and expanding the knowledge from plasma 
sterilization and plasma medicine into the plasma agriculture 
sector is a logical step. PTW can be generated in bulk liquids 
and applied as a sanitizer [6,7]. It has been shown that PTW 
retains or even promotes food quality while effectively 
inactivating microorganisms with minimal impact on chemical, 
nutritional, texture, and sensory attributes of food produce 




[2,8]. Significant water conservation in fresh produce washing 
and protective treatment has been achieved by replacing bulk 
wash water with plasma-activated micron- and submicron- 
water mist. In addition to significant decrease of wash water 
consumption, the plasma-mist processing of fresh produce 
demonstrated high efficacy of bacterial inactivation [9]. 
The efficient generation and transport of reactive species into 
the liquid is the key to advancing the widespread use of plasma 
devices for microbial inactivation, nitrogen fixation and for 
treating different source water, as discussed next. Regardless of 
the application, the process owes its strong chemical 
conversion/oxidation and disinfection capabilities to the 
generation of reactive oxygen and nitrogen species (RONS) in 
the gas phase and their subsequent solvation into the liquid 
phase and also has the advantage of synergistic effects of high 
electric fields, and UV/VUV light emissions. The best 
performing plasma reactors feature a high surface area to 
volume ratio which ensures increased solvation rates [10]. 
Plasma in contact with a liquid on large surfaces, plasma in 
bubbles in liquids, and water droplets in the plasma have all 
been utilized to increase this ratio [11]. 
 
Purification of water supplies: 
The first report on utilizing electrical discharge plasmas to 
directly degrade organic contaminants dates back to the 1980s 
when Clements et al. reported decolorizing a dye by using an 
electrical discharge within a liquid [15]. Since then, over a 
hundred different plasma reactors have been developed to treat 
a range of contaminants of environmental importance including 
pharmaceuticals, herbicides, pesticides, warfare agents, 
bacteria, yeasts and viruses using direct-in-liquid discharges 
with and without bubbles, and discharges in a gas over and 
contacting the surface of a liquid giving rise to electrohydraulic 
reactors, bubble reactors, spray reactors, hybrid gas-liquid 
reactors, falling water film reactors, etc. Different excitation 
sources including AC, nanosecond pulsed and DC voltages 
have been utilized to produce pulsed corona, corona-like, spark, 
arc, and glow discharges, among other discharge types. Plasma-
based water treatment (PWT) generates a range of RONS and 
other species, as explained in the previous section, requires no 
chemicals, and can be optimized for batch and continuous 
processing. The best performing plasma reactors effectively 
utilize plasma-generated species by concentrating the 
contaminants at the plasma-liquid interface and, as noted 
earlier, feature high surface area to volume ratios. However, 
despite the obvious benefits and advantages of PWT, the 
technology is only now reaching a level of development where 
it can be commercially used to treat emerging and legacy 
contaminants, as demonstrated recently on pharmaceutical 
waste [16] and groundwater contaminated with poly- and 
perfluoroalkyl substances (PFAS), Figure IV.2 [17]. 
PWT is generally considered a highly energy intensive 
process and a significantly more complex technology compared 
to the existing advanced oxidation processes. However, the 
scientific evidence to support these claims is scarce and often 
misleading as the plasma-based treatment of PFAS has been 
shown to outperform all existing destructive technologies in 
terms of energy efficiency and treatment time on bench and 
pilot scales by an order of magnitude [18]. To overcome the 
widespread skepticism towards plasma as an advanced 
oxidation technology and position the process at the forefront 
of water purification, the technology cannot be simply as good 
as the other oxidation processes but significantly better and able 
to treat a wide range of common water constituents. 
 
Fig IV.2. A commercial 10 gpm water treatment system based 
on electrical discharge plasma (courtesy of Plasma Research 
Laboratory, Clarkson University). 
 
Decontamination of air supply: 
Another use of plasma attracting significant interest is the 
treatment of air focused both on inactivation of airborne 
pathogens in air flows, as well as on their chemical cleaning. 
The recent coronavirus related problems, environmental 
protection challenges, as well as the growing threat of 
bioterrorism have brought into focus the need for effective 
methods to decontaminate and sterilize not only different 
surfaces, but also gases and especially air. In the early 2000s, 
most of the plasma-based air sterilizers have been successful 
only when coupling the plasma technology with high efficiency 
particulate air (HEPA) filters to both trap and kill 
microorganisms [20]. Usually, such coupling of filtration and 
plasma systems means trapping the micro-organisms with the 
filter followed by sterilization of the filter using non-thermal 
plasma discharges.  
A few studies, some inspired by the COVID-19 pandemic 
and recently reviewed by Mohamed et al. [21], have shown the 
efficacy of plasmas in inactivating airborne pathogens without 
the use of a filter specially to prevent virus transmission. Most 
commonly, dielectric barrier discharges (DBD) are used in 
different configurations, see Figure IV.3 for an example. DBDs 
offer the advantages of operating in ambient air and at room 
temperature. As mode of action, the short-lived reactive species 
OH and singlet oxygen have been suggested. Hence, the most 
promising results reported in literature were obtained when 
aerosols were passed through active plasma volume (rather than 
effluent).  The challenge of air treatment in ventilation systems 
is the short residence time on the order of subseconds of the air 
inside the active plasma region. 






Fig IV.3 Pathogen Detection and Remediation Facility (PDRF): 
above - general view, below - Dielectric Barrier Grating 
Discharge (DBGD) with air sterilization chamber. [23] 
 
Plasma air treatment, similar to plasma water treatment, is 
generally considered a highly energy intensive process and a 
significantly more complex technology compared to the 
existing air cleaning technologies. However, the current gold 
standard for the reduction of airborne pathogens is filtering 
them out with HEPA filters. These filters effectively retain 
particles, such as bacteria, viruses, and pollen without 
inactivating them. The filters cause significant pressure losses 
in heating, ventilation, and air conditioning (HVAC) systems 
giving rise to higher energy and maintenance costs. The HVAC 
system itself has to be designed for the pressure losses which 
does not allow for a later upgrading of the HVAC system with 
such filters without substantial costs. Especially during the 
COVID-19 pandemic, air cleaning systems that can be installed 
in existing HVAC systems would have been of great advantage.  
As the Decadal Assessment of Plasma Science conducted by the 
National Academies of Science, Engineering, and Medicine 
stated in May 2020: “…we may have missed an opportunity to 
have another tool at our disposal to aid in the current health 
crisis” [22]. 
 
IV.2 Challenges and Proposed Solutions 
 
Present and Future Challenges 
 
Plasma treated water for the food cycle and food safety: 
To date, most of the literature available using PTW for 
fertigation focuses on plant growth in early growth stages, 
typically in soilless systems, as recently reviewed by Ranieri et 
al. [1]. The effect of PTW on plants needs to be studied beyond 
the seedling stage for the process to become a viable alternative 
for agriculture. Further, knowledge about the effects of PTW on 
plant growth in actual soil systems and the impact of PTW on 
soil health and the microbiome structure is limited. The effect 
of other RONS generated in PTW beyond NO3- is also not well 
understood. Further research is needed on H2O2 and NO which  
may act as signaling molecules and were proposed as strategies 
to enhance crop stress adaptation and to prolong shelf life [12]. 
To understand the impact of PTW on the whole plant and its 
ecosystem, multi-disciplinary research approaches including 
plant biologists, soil scientists, microbiologists, and plasma 
scientists and engineers are necessary.   
For the translation of laboratory results to field conditions, 
the impact of organic matter in water on the plasma chemistry 
also needs to be considered and studied. Tap water or well water 
is typically used for irrigation in greenhouses and fields. It is 
well known that the buffering capacity of tap water influences 
the liquid chemistry [11,13]. While the use of deionized or 
ultrapure water in the lab is justified for the reproducibility of 
results and to gain fundamental understanding in simpler 
systems, the presence of organic matter that may become part 
of chemical reaction pathways [14] needs to be studied in more 
detail to understand, optimize, and eventually commercialize 
PTW for nitrogen fixation.  
The use of PTW or plasma-activated mist in food safety 
applications is a promising field. However, limited information 
is available about the impact on produce on a molecular scale 
beyond pH, color and texture. Some studies report discoloration 
or decrease in firmness after exposure to PTW, some reported 
no reduction in terms of vitamins while others reported 
increased vitamin D content, for example. The scientific 
community is using a variety of different plasma sources, with 
different excitation mechanisms, gas compositions, different 
liquid volumes and inconsistent times between PTW 
preparation and use. Due to the transient nature of many 
reactive species believed to be crucial for inactivation of 
bacteria, the time between PTW preparation and application is 
of significant importance, yet not always reported in the 
literature. Given the varieties of produce and plasma systems 
used, it is difficult to understand the fundamental science of 
PTW interacting with fresh produce.  
 
Purification of water supplies: 
Despite the convoluted effects of a multitude of parameters 
affecting the performance of plasma reactors, there is increasing 
evidence that the current plasma reactors are superior for the 
treatment of surfactant compounds (e.g., PFAS, foams and 
dyes) but are unable to competitively treat non-surfactants that 
in reality constitute the majority of the compounds of 
environmental importance. Therefore, increasing the 
conversion efficiency for the treatment of non-surfactants to the 
levels of surfactant-like compounds, and increasing the energy 
efficiency and throughput for the treatment of all compounds 
represent and remain the key challenges for PWT. 
The slow progress in the development and scaleup of plasma 
reactors in general is rooted in three fundamental challenges. 
The first one relates to the lack of understanding of the basic 
processes in the plasma, in the bulk liquid and at the plasma-




liquid interface, including the nature of their interaction. The 
second challenge surrounds the plasma reactor design and the 
lack of understanding of the extent to which classical chemical 
reactor design theory is applicable to the development of 
(heterogeneous) plasma reactor systems. There also exists a 
large gap between the fundamental discoveries and translation 
of those discoveries into engineering solutions. The plasma 
reactor scaleup and the applicable scaling laws belong to the 
third category of challenges.  
The plasma reactor development for water purification 
purposes has been and still is largely trial and error, with 
research predominantly conducted in simple systems 
containing a single compound and using a range of different 
plasma excitation sources. Plasma diagnostics to quantify the 
plasma physics and chemistry remains a challenge. The bulk 
liquid composition and transport have been recognized as 
significant factors affecting the reactor performance and more 
research is needed using techniques such as laser-induced 
fluorescence (LIF) and particle image velocimetry (PIV) 
coupled with kinetic experiments to determine the relative 
importance of diffusive and convective mass transport and 
elucidate their individual roles in compound degradation 
[24,25]. For a range of organic compounds, we are still unable 
to differentiate among different plasma agents responsible for 
their degradation, which hinders the plasma reactor design and 
optimization. The roles of individual ROS, RNS, V(UV), ions, 
metastables and solvated electrons including that of the electric 
field are largely unknown due to the numerous issues associated 
with the existing techniques, protocols, assays, and commercial 
kits that have been developed. It is largely due to the absence of 
the adequate probe(s) and/or techniques to measure the 
concentrations of dissolved short-lived species that the 
community is still unable to learn how to control the plasma and 
bulk liquid chemistry with the input operational parameters and 
ultimately maximize the production of oxidative species or 
reductive species (plasma is a both an oxidative and reductive 
process) for a particular water treatment application. 
To understand the fundamental science behind interfacial 
dynamics and develop accurate theories that describe process 
performance, more data is usually better. However, to upscale 
a plasma reactor by any degree requires information on only the 
key processes and design parameters that could be empirical. 
To date, ensuring a high plasma area to liquid volume ratio has 
been identified as the critical requirement but also the key 
technological challenge in the plasma reactor scaleup [19]. 
 
Decontamination of air supply: 
Three major challenges are related to successful commercial 
and industrial application of plasma sterilization and cleaning 
of air flows: energy cost, productivity, and selectivity. 
1. Energy cost of plasma air treatment. Plasma air 
decontamination systems consume electric energy, 
which determines most of the operational cost of the 
relevant technologies. The electric energy cost is a 
crucial challenge of plasma air cleaning since the 
majority of conventional and novel competing air 
cleaning technologies are less electric energy intensive 
(or do not consume electric energy at all). Cost is 
especially important for decontamination of large air 
volumes. Analysis of cost effectiveness shows that to 
be economically viable the electric energy 
consumption must be below 1-3 × 10-3 kWh/m3 of air 
for decontamination of large air volumes. 
2. Thruput (capacity) of the plasma system. To be 
effectively commercialized, the air flow capacity of 
plasma systems should be scaled up to typical 
industrial/commercial levels of thousands of m3 per 
hour. Even at the expected energy effective regimes 
(electric energy cost below 1-3 × 10-3 kWh/m3), the 
airflows on the level of thousands of m3 per hour 
require at least 10 kW of cold plasma power. This is a 
significant engineering challenge that necessitates the 
development of powerful cold plasma discharges and 
building relevant power supplies with high efficiency 
matching characteristics. 
3. Selectivity of air cleaning processes. Plasma systems 
may generate non-acceptable treatment byproducts 
like ozone, nitrogen oxides, etc. These byproducts 
restrict types and operational regimes of applied non-
thermal plasma discharges. Detailed understanding of 
relevant plasmochemical process mechanisms and 
analysis of plasma system combination with other air 
treatment approaches are still needed. 
 
Proposed Solutions  
 
Plasma treated water for the food cycle and food safety: 
As a common theme for plasma agriculture applications, 
upscaling is one of the biggest challenges. In order to optimize 
the process and to design highly efficient plasma-water or 
plasma-mist reactors, more fundamental understanding is 
required of a) the kinetics and collisional processes in the highly 
non-equilibrium plasma regime, b) the (efficient) transport of 
species into the liquid, and c) the plasma-generated species 
required for the optimum outcome. For a more fundamental 
understanding, advances in diagnostic capabilities in the liquid 
phase and at the plasma-liquid interface are required, as well as 
advances in modeling, capturing the properties of non-
equilibrium plasma kinetics and the transport through the 
plasma-liquid interface into the liquid. The effect of charged 
species and photon-induced effects, as well as reactions 
involving short-lived species like atomic oxygen have yet to be 
addressed as many reaction rates, cross sections, and rate 
constants are unknown. Calculations and measurements of 
these unknown quantities are critical for advancing the 
understanding of the plasma-liquid interfacial processes.  
Regarding the applications of plasma-treated water in the 
food cycle and food safety arenas, the plasma parameters 
affecting the enhanced plant growth and resilience, healthy soil 
and nutrient management must be better understood to optimize 
the process. While the effect of plasma-generated nitrate or 
ammonium as fertilizer is well known, other RONS and their 
potential benefits for plant growth and the plants’ ecosystem 
have not been studied in detail yet. For food safety applications, 
the impact of RONS in the liquid on food quality and nutrients 
is also not well understood. The use of appropriate controls, e.g. 
nitrate, nitrite, and hydrogen peroxide controls with a 
concentration matching the concentrations in PTW, would help 
to identify mechanisms and to pave the road for upscaling and 
commercialization efforts. 




Purification of water supplies: 
One of the biggest challenges in the design, optimization and 
scaleup of highly efficient plasma reactors is finding the way 
for the community to work together towards this common goal 
and build on each other’s findings. A large volume of literature 
currently exists on the effectiveness of over a hundred different 
plasma reactors for treating dozens of different compounds and 
biological species. And while each of these studies is 
unarguably useful and informative, systematic comparison of 
the compound(s)/microorganisms studied is needed, including 
their degradation/inactivation rates and starting concentrations, 
reactor types, discharge energies, excitation sources, and 
treatment volumes to be able to deconvolute and extract any 
information regarding the key design and operational principles 
that control the system performance. While such studies are rare 
due to their laborious nature, they are extremely informative 
and may set empirical guidelines for the plasma reactor design 
[19].   
To remedy this issue and essentially calibrate multiple 
concurrent reactor design and scaleup research efforts, the 
community should agree on using and characterizing a 
reference plasma treatment system similar to the COST 
Reference Microplasma Jet that is currently being used in the 
biomedical community to identify the parameters and processes 
that guide and control the plasma reactor design and the process 
performance. An example of such a system would be a point 
gas discharge in a noble gas contacting the surface of the treated 
liquid with a grounded plate immersed in the liquid. Common 
electrode material, electrode dimensions, reactor volume, and 
the compound/microorganism treated would be chosen. 
Beyond these set parameters, immediate new research would 
welcome investigations on the excitation source types, process 
gas types, mixing, etc. and include advanced 
spectroscopic/laser techniques to quantify the plasma physics 
and chemistry. In the liquid, complementary analytical 
measurements would be focused on the quantification and/or 
identification of the extent of the compound degradation, 
byproducts and their toxicity, reaction mechanisms and the 
species responsible for the chemical transformations. 
Concurrently, techniques such as LIF and PIV would be applied 
to determine the location of degradation/inactivation, visualize 
the flow and measure the velocity fields in the liquid. The 
outcomes of these fundamental investigations would assist in 
determining the limitations and the advantages of the 
technology, its level of performance with respect to the existing 
technologies and, if applicable, the key technical challenges 
that must be overcome before the technology can be upscaled. 
Once the experimental, design and operational conditions under 
which the system performs equally well or better compared to 
the existing technologies are determined, then the actual 
scaleup can commence.  
 
Decontamination of air supply: 
Meeting the challenges of energy efficiency, air flow 
capacity, and process selectivity requires: 
1. Effective combination of plasma technologies with 
conventional approaches, including scrubbing, 
filtration, etc. allows for a significant decrease of the 
total process energy cost. In particular, combination of 
plasma treatment with filtration and scrubbing limits 
plasma treatment to only charging and partial 
oxidation of biological and chemical pollutants, thus 
decreasing electric energy consumption in orders of 
magnitude. 
2. Development of effective and not-expensive cold 
plasma power supplies operating on the power level 
up to hundreds of kW with an appropriate source that 
has plasma load matching characteristics. 
3. Plasma-chemistry optimization to suppress generated 
non-acceptable treatment byproducts like ozone, 
nitrogen oxides, etc. It requires, in particular, analysis 
and characterization of non-uniformity of plasma-
chemical processes in air. 
 
To conclude, there is substantial interest in water treatment 
using electrical discharge plasmas, especially for the 
degradation of legacy and emerging contaminants or point-of-
use fertilizer production. Similarly, the recent COVID-19 
pandemic inspired renewed interest in alternative air treatment 
methods. The Decadal Assessment of Plasma Science by the 
National Academies of Science, Engineering, and Medicine 
released in May 2020 states: “The central challenge in many of 
the proposed applications of LTP activated processes to energy, 
water, food and agriculture is in scaling. Even if plasma can be 
shown to be effective on small laboratory scales, the process 
must be scaled sufficiently to make it useful in an industrial 
setting, whether in the factory or the corporate farm.” [22] The 
feasibility of current plasma devices for the treatment of water 
and air has been demonstrated on the bench scale; however, 
their widespread commercial and industrial applicability 
necessitates further optimization of energy efficiency and the 
actual scaleup of the devices and their plasma-generating 
networks to the required levels. For the wide adoption of the 
plasma-based devices, the process cannot be just as good as the 
existing technologies but significantly better. 
While there have been significant advances in understanding 
the chemistry and physics of the single and multiphase (gas-
liquid) plasma systems, these have been generally studied 
separately, either from the plasma or from the bulk liquid side. 
To understand the processes that control chemical conversion 
and energy efficiency is crucial for the scaleup of any plasma 
system and requires a holistic multidisciplinary approach that 
identifies the key measurements, sets of data, and/or the reactor 
design element(s). In other words, to translate fundamental 
findings into engineering solutions, the community has to 
rethink its approach towards the common goal of plasma air and 
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V. LTP FOR WOUND HEALING 
S. Bekechus 
V.1 Current State 
Non-healing and chronic wounds are a major burden to both 
patients and healthcare systems. About two decades ago, the 
application of low-temperature plasma (LTP) for wound 
healing was among the first medical problems envisioned to be 
addressed using gas plasma technologies after finding 
promising antimicrobial effects of LTP in the 1990s [1-3]. 
However, taking the concept into the clinical routine took place 
only in the last decade. The requirements for bench-to-bedside 
concepts are multifold. The plasma device must be safe, 
generating a reproducible plasma, manufactured based on 
quality management procedures, receiving appropriate 
accreditation by authorities, fulfill reasonable criteria for basing 
business models on existing needs in the health care market, 
and, ultimately, medical doctors willing to explore such novel 
tool in the clinical setting.  
The current state of LTP in wound healing can be described 
from several perspectives, such as i) regional practice, ii) 
preclinical vs. clinical, iii) and the plasma devices' 
specifications. From the regional perspective, LTP-mediated 
wound healing in the clinical setting is most advanced in central 
Europe, especially Germany. All plasma devices that were 
accredited by official medical authorities to treat chronic 
wounds within dermatological centers were engineered and put 
into practice in Germany. According to the directive on Medical 
Device Regulation (MDR, EU 2017/745), these devices can be 
used across the European Union. Official numbers of devices in 
the field are not available, but based on personal 
communications, it is estimated that there are a few hundred 
devices currently sold to or rented by dermatological centers 
and practitioners. There are efforts in, e.g., the U.S. and the 
Republic of Korea to achieve similar local authorization for 
plasma devices aimed at targeting chronic wounds in humans. 
It is emphasized that this text only focuses on clinical and 
human cases of wound healing, not on cosmetic or veterinary 
applications. 
For clinical wound healing, several hypotheses exist to 
explain the benefits from LTP exposure, suggesting several 




mechanisms simultaneously at play to promote wound healing. 
Usually being less than 1 log (90%), the antimicrobial efficacy 
of LTP-treated wounds is documented but overall modest [5,6], 
also when analyzed ex vivo [7]. Accordingly, a recent 
prospective, randomized, placebo-controlled, patient-blinded 
clinical trial comparing plasma vs. antiseptics in a head-to-head 
study indicated LTP-promoted wound healing independent to 
antimicrobial efficacy as patients in all groups received 
antiseptics. The effect of LTP-derived electric fields in wound 
healing is unclear, especially since there is a lack of studies on 
intensity-matched exposure of electric fields alone in 
appropriate in vivo wound models. The mild heat transferred to 
the wound from the LTP is rather beneficial than detrimental to 
wound healing [8]. The dominant effector hypothesized to drive 
LTP-induced wound healing is reactive oxygen and nitrogen 
species (ROS/RNS) [9,10]. Albeit direct clinical evidence of 
the roles of ROS/RNS is challenging to obtain, overwhelming 
data is supporting this idea, as described by D. B. Graves in his 
2012 review [11]. In addition to this, recent work in LTP-
treated patient wounds suggests plasma to spur on 
microcirculation and tissue oxygenation in superficial and 
deeper layers [12,13].  
 
Fig V.1 Hyperspectral imaging of wounded ear (left) with 
orange wound region in control mice (top) and enhanced signal 
generation in the plasma-treated wound (bottom). Boxplots 
show quantitative data for several parameters of hyperspectral 
imaging. Figure is adapted from [4]. 
 
Preclinical evidence of plasma-treated wounds in mice from 
Schmidt et al. confirmed these findings [14] and suggested an 
important role of focal adhesions and complexes and matrix 
remodeling in plasma-treated wounds [4] (see Figure V.1). 
Most importantly, an array of in vivo data in non-infected 
wounds of different origins (e.g., punch biopsies, burn, and 
laser-induced), animal species (e.g., mice, rats, and sheep), and 
locations (e.g., back and ear) have shown plasma treatment to 
promote healing in the absence of infection [15-22]. This 
markedly substantiates the idea of redox control of wound 
healing via plasma-derived ROS/RNS. The discussion on 
mechanisms is beyond this article's scope, but it has been 
recently suggested that the redox-regulating transcription factor 
Nrf2 and altered immune cell infiltration take part in plasma-
accelerated healing using the kINPen [23]. Also, the 
mechanism of action of the accredited microplaster plasma 
device was delineated to redox action and stimulation of 
wound-resident cells of the body [24-27]. Details on in vitro 
findings were summarized recently [28]. 
Regarding the perspective on the types of cold plasma 
sources, only devices in clinical practice are discussed because 
an overwhelming number of plasma devices have only been 
covered in relatively few papers and rarely in a clinical setting, 
while usually lacking accreditation. Of the three devices 
currently marketed based on thorough clinical experience and 
medical product guideline compliance or FDA approval 
specifically for chronic wound healing in dermatology, two are 
DBDs (PlasmaDerm from Cinogy and SteriPlas from Adtec), 
and one is a jet (kINPen MED from neoplas med). All have 
been investigated in clinical trials, as summarized before [29-
31]. Two more devices from Germany, PlasmaCare from 
TerraPlasma (clinical trial completed) and a silicon-based 
plasma-plaster called CPTpatch from the INP spin-off company 
ColdPlasmaTech (clinical trial in preparation) are within 
authorization phases. The DBD device PlasmaCare is 
innovative because of its battery-driven nature, making it an 
excellent option for ambulant and home wound care. The 
CPTpatch is a single-use wound dressing that is planned to be 
left on the wound to ignite a plasma directly in the wound bed 
multiple times. This status suggests a dominance of DBD 
devices over jets in present and future medical plasma wound 
care. Notwithstanding, clinicians repeatedly emphasize the 
scalpel-like precision treatment option that comes with plasma 
jet systems. Especially experienced wound nurses and health 
care practitioners know that some areas in chronic wounds are 
more problematic than others [32], which can be effectively 
targeted with plasma jets in a loco-regionalized manner and, 
e.g., with individual treatment times. Regardless of the device 
type, the plasma therapy complements and does not replace 
existing wound care measures. Critical steps such as wound 
debridement and dressing change remain to be vital for 
therapeutic success. 
 
V.2 Challenges and Proposed Solutions 
The challenges and opportunities in the transdisciplinary 
field of plasma wound are covering knowledge from physics, 
biochemistry, and medicine are vast. A detailed discussion, 
especially individual cell type responses to plasma treatment, is 
therefore out of scope of this work. The most critical aspects 
will be discussed nevertheless. 
The perhaps greatest asset and caveat at the same time in plasma 
medicine is the large number of devices reported on. While this 
is beneficial for exploring the science behind the physics and 
biology in plasma medicine, it is detrimental to clinical practice. 
An ideal clinical plasma device would have been accredited 
across all continents to spur global research efforts, clinical 
trials, and, ultimately, a certain degree of comparability 
between results. These would then be independent of the device 
and depend on treatment parameters, such as treatment duration 
per cycle, frequency of treatments per week, onset indications 
of treatment, and offset indications for stopping plasma therapy. 
Currently, published evidence on such aspects are is absent, 
hampering the motivation of clinicians less experienced with 
plasma therapy to implement this technology into their 
treatment portfolio. Hence, future plasma therapy needs clear 
guidelines that state the boundary conditions of application, 
which less plasma-experienced clinicians can also follow. Such 
guideline is currently set up in Germany within the framework 
of the so-called AWMF catalog of treatments.. Such medical 
guidelines would allow reimbursement of plasma therapy, a 
critical step in the German healthcare system that draws the line 
between reimbursed standard therapies covered by the 
obligatory healthcare insurance and non-reimbursed 
experimental therapies covered by the patient or medical 




doctor. After all, the additional treatment costs have to 
significantly reduce the long-term costs of existing wound care 
to be regarded as superior to existing therapies. In general, low-
cost accredited plasma devices commercially available globally 
will be key for taking plasma wound therapy outside its current 
niche, with great potential benefits, especially in developing 
countries. 
From a clinician scientist's point of view, several points are 
unclear in plasma wound therapy, for example: What is the best 
treatment schedule in terms of duration and frequency? Should 
the entire wound be treated or, e.g., predominantly infected 
parts? Are some plasma devices superior in some types of 
wounds over others? What is the role of infection? Are there 
common traits in patients that do not respond to plasma wound 
therapy? Is optimization possible of existing medical product 
DBD and plasma jet device, and if so, how specifically? What 
role plays the wound etiology underlying the disease, e.g., 
diabetes? Should the treatment regimen be adjusted for wound 
location and size? Is plasma therapy affecting existing wound 
care measures positively or negatively, and can it be combined 
with other therapies such as hyperbaric oxygen or vacuum? 
This shortlist of questions exemplifies the need for applying 
and reporting clinical plasma wound therapy experiences to a 
much greater extent than currently being the case. Ideally, only 
a few plasma devices should be used globally in such settings 
to build knowledge consecutively instead of serially, as is 
currently the case. Other, although admittedly less complex 
technologies based on physical principles that had entered 
medical practice, such as radiotherapy and 
electrochemotherapy, went similar routes of standardization. 
From a preclinical perspective, understanding the interface 
reactions of plasma with the target tissue is the perhaps least 
explored but most needed challenge in plasma wound therapy 
and medicine in general [28]. First of all, it needs to be 
understood that there is no genuine bulk liquid in wounds. In 
addition to wound cells and microorganisms, amino acids, 
proteins, lipids, and nucleic acids will always be close by to the 
plasma streamers, offering plenty of reaction partners for 
plasma-derived ROS/RNS. It is therefore plausible that the role 
of short-lived ROS/RNS is much greater than in liquid-rich 
laboratory assay systems with cells, in which diffusion 
distances between the ROS/RNS source (plasma) and the target 
(cells) are too high for the short-lived ROS/RNS to maintain 
reactivity. The argument that the tissue is composed of water is 
also void. A majority of water is in the cytosol of cells, a 
compartment packed with redox-active proteins, adding to the 
already complex plasma chemistry. Three conclusions follow 
from this argumentation. First, it is vital to increase the 
understanding of which types of ROS/RNS reach the target to 
what extent. Unfortunately, the number of tools available in 
redox research to distinguish the different types of ROS/RNS 
on a quantitative scale is limited. For the fluorescent redox 
indicators proposed to be specific, virtually all of them have 
cross-reactivity with multiple types of ROS/RNS, especially 
when introduced into cells [33,34]. Second, research on non-
cellular targets as mentioned above needs to be identified to 
clarify their role and contribution to plasma-mediated cellular 
effects. The fact that oxidative modification of such targets can 
be of biological and immunological relevance has recently been 
demonstrated for the kINPen [35,36], apart from a broad array 
of work in the field of redox biology for single ROS/RNS [37-
39]. Third, and based on the questions proposed from a clinical 
perspective, it is critical to understand that only animal models 
recapitulate the wound environment to a sufficient extent to 
allow true preclinical conclusions on plasma parameters and 
biological effectors. The contribution of the immune system, 
which cannot be accurately mimicked in vitro, is highly critical 
for the onset and offset of the different wound healing phases 
to allow complete healing [40-42]. Other vital aspects, such as 
angiogenesis and matrix remodeling, also take place in 
appropriate test systems only. By directly comparing infected 
vs. non-infected wounds, final conclusions may also be drawn 
towards the role of antimicrobial plasma effects in supporting 
healing responses. The role of cells of the immune system in 
plasma-enhanced wound healing might be analyzed using 
immune-deficient mice or antibody-mediated depletion. 
From the plasma device perspective, the field of plasma jets 
currently offers the greatest opportunity of improvement. Jets 
have the caveat of being limited to a small area, while patient 
wounds can be significantly large, leading to long exposure 
times and ultimately also costs. Several groups have mitigated 
this issue using multijet arrays [43,44] or are currently working 
on this. Plasma jets (and gas-driven DBDs) also offer the 
opportunity of tuning the feed gas towards application-oriented 
effects, a principle shown multiple times by several groups 
across in physical, biochemical, antimicrobial, biological, and 
in vivo characterization [45-50], including wound healing in 
rodent models [15,51,52]. Ultimately, however, it might be 
more reasonable to optimize existing plasma devices that have 
received or are planned to receive accredition as medical 
products to facilitate the translation of data and knowledge from 
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VI. LTP IN DENTISTRY 
C. Jiang 
VI.1 Current State 
The earliest application of gas discharges in dental practice 
dates back to 50 years ago; in 1970s, plasma-sprayed titanium 
(Ti) or Ti plasma-coating for metals and ceramics were used for 
oral implants[1]. In the late 80s and early 90s, more applications 
of low-pressure plasmas in dentistry emerged, including dental 
instrument sterilization[2-4] and surface treatment of 
biomaterials such as denture, splint ribbon, composite post, and 
dentin to assist miscellaneous dental procedures[1, 5, 6]. It was 
not until the early 2000s, however, direct treatment of teeth and 
oral surfaces for potential chairside uses became possible due 
to the development of non-thermal atmospheric pressure 
plasma (NTAP) based technologies[7]. Applications of plasmas 
in dentistry have since flourished and entwined with other new 
technologies in different dental specialties for advancement of 
the relevant techniques. Reviews or updates on similar topics 
frequent in dental, medical and engineering journals, especially 
in the past decade[5, 8-12]. The status/update reported here 
hence serves as an addition but not a replacement to the 
previous reviews on the applications of NTAPs in dentistry.  
According to the potential clinical use, applications of the 
plasma-based technology can be categorized as direct and 
indirect uses of plasma. Direct uses of plasma refer to applying 
direct plasma treatment on dentin, gum, implant, or other dental 
objects of a patient in a dental office for chairside uses. Any 
other uses of plasma in dental practice such as the use of plasma 
for cleaning, preparation or modification of dental materials and 
surfaces, which can be achieved in a laboratory and outside of 
a dental office, belong to the indirect uses of plasma. Due to the 
different application settings of direct and indirect uses of 
plasma, the requirements and challenges for technology 
adaption are hence significantly different, which also impact the 
state of the technology development for specific applications. 
The direct uses of plasma can be classified as three areas in 
dentistry: periodontal, endodontic and prosthodontic 
treatments. While the antimicrobial effects of plasma play the 
most important roles in the first two areas of applications, 
surface modification to improve the adhesion properties or 
change the coloration of dentin is the main cause for the 
prosthodontic treatment. Table VI.1 lists the specific 
applications that can be classified in different dental practice 
areas, the related study models, plasma sources used, and their 
corresponding status. Periodontal treatments include both 
removal pathogenic microorganisms or biofilms from cavities 
(such as caries) or implants that were previously applied in a 
patient and causing peri-implantitis. For research effort, cavity 
cleaning may overlap with root canal disinfection, although the 
choice of microbial strains and treatment substrates may vary. 
For root canal disinfection, accessibility of the plasma-induced 
disinfecting effect into the apex and the rest tubular structures 
of a root canal is an additional challenge for the application, and 
hence the outcome from ex vivo and in vivo studies would weigh 
more to help evaluate the potential success of the technology. 
The status of both caries removal and endodontic disinfection 
is hence similar: it is evident that NTAP treatment can be as 
effective as the use of bleach such as 5-6% NaOCl or 2% CHX, 
while the combination of NTAP with bleach irrigation can 
achieve even better disinfection outcome[9, 19-22]. Studies for 
implant surface cleaning using NTAPs are fewer comparing to 
other areas of applications. Although the efficacy of 
atmospheric plasmas, powered by pulsed microwave (MW) or 
radio frequency (RF), on implant surface decontamination has 
been demonstrated, safety studies of these plasma applications 
are lacking. Additionally, a recent study showed that the effect 
of plasma is not significant for implant surface disinfection 
when the plasma treatment was added to an air-polishing 
protocol[16]. Prosthodontic treatments are dental procedures 




for esthetics or cosmetic restorations. They include tooth 
bleaching and dentin treatment for bonding to resins. The tooth 
bleaching application of plasma uses the surface modification 
properties of plasma and enhances the bleaching activity of 
bleach agents on dentin surfaces. Studies have shown the 
combination of NTAP and bleach agents enhanced the 
bleaching effectiveness by a factor of 3 or higher[26, 27]. For 
the dentin treatment, a recent systematic review on effect of 
NTAP on adhesives resin–dentin micro-tensile bond strength 
(μTBS) showed that NTAP application could enhance resin–
dentin μTBS of etch-and-rinse (ER) adhesives or universal 
adhesives applied in the ER mode[9]. Some studies showed that 
an optimal dosage (e.g. treatment time) was important to 
achieve better interfacial bonding strength or μTBS, while 
overtreatment resulted decreased interfacial bonding 
strength[30]. 
The indirect uses of plasma in dentistry include surface 
modifications of implants for implantology or oral surgery, 
improving interfacial bonding strength or adhesion of dental 
objects used in periodontics or prosthodontics, and sterilization 
of dental instruments. Surface modification using plasmas, both 
low-pressure and atmospheric pressure, is the most widely used 
plasma-induced process that impacts various applications 
including surface modification/activation of Ti, Zr, or CaP-
coated implants, dental alloys, improving interfacial bonding 
strength or adhesion of resins, resin composites, glass fibers, 
ceramics, polyetherketoneketone (PEKK), and dentures. For 
decontamination of dental instruments, inactivation of dental 
pathogens with ion bombardment and oxidation induced by 
low-pressure non-equilibrium plasmas used to dominate the 
plasma applications for sterilizing endodontic files or other 
operative instruments[5, 10]. Although most of these indirect 
applications started with low-pressure plasmas and may still be 
able to use low-pressure plasmas, the use of NTAP eliminates 
the need of a vacuum system, potentially achieves faster 
cleaning process and can hence reduce the cost of operation 
substantially. As a result, NTAP has been attracting more and 
more interests in research and development and may gradually 
replace the use of low-pressure plasmas in almost every dental 
field.  
The in vitro and in vivo studies demonstrated that NTAPs 
could enhance surface colonization and osteoblast activity, and 
accelerate mineralization of implant (e.g., Ti and Zr) surfaces, 
as well as improve osseointegration of implant[5, 10, 31]. The 
antimicrobial effects of NTAPs facilitate biofilm removal and 
prepare a clean surface of an implant[5, 10]. Additionally, the 
combination of mechanical and NTAP treatments may result in 
surface “rejuvenation” against peri-implantitis by activating the 
synergistic antimicrobial effects and surface improvement[5, 
10].  
 













dental pathogens and 
pathogenic biofilms 
grown on well-plates, 
agar, HA discs, 
dentins and other 
substrates, in vitro 
NTAP plasma 
jets, pulsed or 
RF, Ar/He + 
(O2) or Air 
Large variations in CFU 
reduction factors depending 
on the substrates and 
plasma treatment dosages.  
In general, plasma effect is 
comparable with the use of 
5-6% NaOCl or 2% CHX 
irrigation on dentin 
surfaces. Biofilms are 






S. mitis, C. albicans, 
P. gingivalis) or peri-
implantitis biofilms on 
Ti discs, Ti implants, 
steel wafers, in vitro or 
ex vivo 
NTAP plasma 
jets, MW or 
RF, Ar/He + 
(O2, H2O) or 
Air 
NTAP was shown effective 
in removing P. gingivalis 
biofilm from titanium discs, 
in vitro.  Comparing with 
other techniques such as 
air-polishing, the effect of 
NTAP is not significant and 
needs more study.  
[16, 17] 
Endodontic Treatments 






E. faecalis, C. 
albicans or multi-
strain endodontic 
biofilms grown in root 
canals or tubular 
structures mimicking 
root canals, in vitro, ex 
vivo, and in vivo  
NTAP plasma 
jets, pulsed or 
RF, Ar/He + 
(O2 or bleach 
solutions) 
In most studies, plasma 
effect is comparable with 
the use of ~3% NaOCl or 
2% CHX irrigation. 
Biofilms are harder to 





Stained or natural 
extracted human teeth 
(sectioned or whole), 
in vitro/ex vivo, rabbit 
teeth in vivo, were 
subject to bleach 
(H2O2, carbamide 
peroxide) in solution 
or gel, combined 
treatment of plasma 




15- 20 kHz) 
AC or pulsed, 
He or Ar 
Combining NTAP and 
bleach improved the 
bleaching efficacy (by a 





HA disc or dentin 
surfaces prepared from 
extracted human or 
bovine teeth, after 
crown removal, 





RF, or low 
frequency AC, 
He or Ar 
Plasma treatment of the 
dentin surface (for an 
optimal dosage such as the 
treatment time) increases 
the interfacial bonding 
strength or μTBS, and 
facilitate the adhesion 
process 
[9, 28-30] 
VI.2 Challenges and Proposed Solutions 
Decades of research activities have led to substantial 
development of plasma applications in almost all areas of 
dentistry. For indirect treatments, the challenges of plasma 
applications are mainly the efficacy of the plasma-based 
technologies and the effective cost compared with other non-
plasma techniques. The increasing uses of NTAPs are making 
the plasma-based technology more economically competitive, 
especially comparing to lasers or UV-light sources required 
techniques. The highly controlled surface modification by 
NTAP treatment is becoming the future trend in oral surgery 
and implantology [10], where chemical functionalization, 
deposition of antibacterial thin films and coatings, and surface 
structuring to create antifouling surfaces impact significantly on 
application outcomes. More importantly, adapting NTAPs into 
additive manufacturing such as three-dimensional (3D) printing 
and polymerization to assist multiple areas in dentistry will 
decisively pin the plasma-based technology in the map of dental 
technologies. The reports of plasma sterilization of 3D printed 
dental objects[32] or removal of chemical gradients inside 
porous structures to enhance cell viability in 3D porous 
scaffolds (Wan, et al. Biomaterials, 2006) for tissue engineering 
are promising start for more plasma-processing assisted 
dentistry [33].    
The road to chairside uses of direct plasma treatments, on the 
other hand, remain more challenging. The large variations in 
treatment outcome, particularly concerning the antimicrobial 
effects of NTAPs[8], and the diverse selections of different 
NTAPs, which can be powered by pulsed DC, RF or MW, 
present dilemmas for dentistry researchers and students to 
decide for the next-step clinical trial. Nevertheless, studies 
designed in a clinically relevant model, such as using multi-
species microbial biofilms from patients grown on a dentinal 
surface or in a root canal as well as animal models have been 
abundant[13, 18, 19], can be the ultimate testing model for ex 
vivo or in vivo studies. Comparisons between NTAP and other 
non-plasma treatment protocols are important. Comparable 
antimicrobial effects of NTAPs against dental biofilms in ex 
vivo root canals or animal models are great milestones in plasma 
applications for periodontal or endodontic treatments. Close 
collaborations between the dentists and plasma engineers are 
essential to identify the effective treatment protocols and 
efficiently use resources for technology advancement. The 
other challenge is the safety concern. The reactive oxygen and 
nitrogen species (RONS) produced by NTAPs have been 
considered playing important roles in antimicrobial processes 
and surface modification, and also known to cause oxidative 
and nitrosative stress to cells and tissue. Nam et al. recently 
conducted a histological safety study in a rabbit model using a 
NTAP for tooth bleaching [34]. The NTAP was based on a 
dielectric barrier discharge configuration, powered by 15 kHz 
AC at 10-kV peak voltage. The working gas was Ar. The gap 
temperature was about 35C. The study concluded that the 
combinational treatment of plasma and 15% carbamide 
peroxide (CP) resulted in the most color change compared with 




15% CP treatment alone, and the combination treatment did not 
indicate inflammatory responses nor thermal damages[34]. The 
authors also noted that the plasma did not cause histological 
damage in oral soft tissues during tooth bleaching[34]. Another 
recent in vivo study conducted by Yao et al. demonstrated the 
antimicrobial effectiveness of a NTAP against apical 
periodontitis in a beagle model, comparable to that of 2% CHX 
irrigation, with no detected structural damage in dentin or tissue 
necrosis at the periapical region[18]. The NTAP was generated 
from a handheld plasma jet device, using He as the primary 
working gas, and powered by pulsed DC at 10 kV and 10 
kHz[18]. The authors commented that modifying the NTAP jet 
by following He through 2% CHX enhanced the antimicrobial 
efficacy[18]. However, the safety study on the modified method 
was not reported. After all, the generation of RONS were 
associated with many technologies in dentistry including lasers, 
photosensitizers, bleaching agents, and even resin cements [35]. 
Hence NTAP is not the only technology may cause safety 
concerns. The critical point here is the dosage control. More 
safety studies similar to the above two examples would help 
pave the way carrying the NTAP-based technology through 
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VII. LTP FOR CANCER TREATMENT 
M. Keidar, V. Miller, S. Bekeschus, D. Yan, H. Tanaka, M. 
Laroussi, K. Ostrikov, and M. Hori 
VII.1 Current State 
In recent years low-temperature plasma, LTP, is increasingly 
being investigated as a possible new modality for cancer 
treatment [1], [2]. The novelty of LTP lies in its multi-factorial 
effects that include reactive oxygen and nitrogen species 
(ROS/RNS) produced in the plasma, physical factors like 
emitted electromagnetic waves and the electric fields that are 
formed when plasma impinges on tissue [3]. Rapid advances in 
LTP technology have allowed great control on the final 
composition and properties of plasma for specific biological 
processes aimed at clinical applications. Specifically in 
oncology, LTP has enabled scientists to explore the 
mechanisms of eliminating cancer cells that would be 
applicable in diverse types of cancers. Focal solid tumors 
require different treatment approaches than more diffuse or 
metastatic tumors. Broadly, the experimental approaches 
encompass two methods of inducing cancer cell death: direct 
killing of cancer cells by LTP in situ and stimulation of immune 
responses by inducing controlled oxidative stress in cancer 
cells. Numerous studies use in vitro 2-D cell culture models, 
and the use of 3-D, in-ovo, and animal models that are very 
much in alignment with the cutting-edge approaches in 
oncology therapeutics, is increasingly being reported. These 
studies expand depth and breadth of knowledge about the 
efficacy of LTP in producing the desired anti-cancer effects and 
the mechanisms of LTP action further enabling improved 
methods of plasma delivery. The encouraging aspect of these 
investigations is that an initial proof-of-concept clinical case 
study has already been performed [4], and its results can be 
utilized to design studies that ask practical questions [5]. 
The widely accepted hypothesis of LTP interaction with cells 
and tissue is based on the notion that chemical elements of LTP 
are stimulating or toxic, depending on their concentration [6]. 
Various unique combinations of these species might provide 
great potential for activation of specific signaling pathways in 
cells where no single component is yet identified as the key 
effector. LTP application to tumor cells can have cytotoxic 
effects both in vitro and in vivo. Some studies suggest that non-
malignant cells are less sensitive to the same regime of LTP in 
some studies, though this is not necessarily always the case [7]–
[9]. These outcomes are believed to be related to the chemical 
species in plasma. The sensitivity of cancer cells to either direct 
treatment or indirect treatment is proposed to be due to redox 
imbalance and to specific antioxidant systems that are linked to 
the expression of tumor suppressor genes like p53 [10]. 
The basic strategy of indirect LTP treatment is the 
application of plasma-treated liquids (PTS) such as cell culture 
medium or aqueous solutions like lactate to kill cancer cells or 
destroy tumor tissues. The anticancer effects are achieved by 
the chemical components, including reactive species and other 
chemically modified substances in these solutions [11]–[13]. 
Typically, PTS are produced through direct contact of LTP with 
the solution during treatment. However, PTS can also be 
produced by the gas discharge within the solution [14], [15]. 
PTS has been shown to selectively kill many cancer cell lines 
in vitro or have anti-tumor effects when directly injected in 
subcutaneous or intraperitoneal tumor models in vivo [16]–[19]. 
Once produced, PTS is independent of plasma source, which is 
an advantage over direct plasma treatment. Treatment by PTS 
eliminates the local effects of electric fields, photons, and 
temperature. Some cancer cell lines, such as the melanoma cell 
line B16F10, show only modest cytotoxicity to the reactive 
species in PTS [20]. PTS also shows promising application in 
the treatment of metastatic cancers as shown in a recent study 
that addresses epithelial-mesenchymal transition (EMT). EMT 
is a process which endows cancer cells with increased stemness, 
metastatic potential, and resistance to conventional therapies. In 
this study PTS was shown to be significantly more effective 
against cancer cells that have undergone EMT than their 
epithelial parent cells. This effect is hypothesized to be due to 
the increased ROS level in the mesenchymally-transitioned 
cells [21]. As a potential pharmacological modality, the 
stability of PTS is an important consideration needing further 
investigation [22]–[24].  
Unlike indirect LTP treatment, direct plasma treatment is 
performed when cells or samples are directly accessible to bulk 
plasma [25]. A layer of physiological solution typically covers 
the cells during direct in vitro LTP treatments [26]. Such a layer 
facilitates the diffusion and formation of reactive species from 
the gas phase to the liquid phase in the medium to produce 
desired biological changes in cells [27]. Physical factors in 
LTP, such as thermal effect, UV, and electric fields, may be 
largely blocked by such an aqueous layer, particularly when it 
is adequately deep. Direct and indirect treatment share many 
similarities [28]: many cellular responses have been widely 
observed in both treatment strategies, including perturbations in 
the cell membrane, changes in mitochondrial structure and 
function (increase in intracellular ROS), and damage to the 
endoplasmic reticulum and DNA [29]. Cell death is the final 
goal and fate of most LTP-treated cancer cells [30], [31]. 
Apoptosis is the primary form of cell death; however, necrosis 
and autophagy-associated cell death have been also reported 
[32]–[35]. 
Direct treatment takes advantage of two unique components: 
short-lived reactive species and physical factors (such as 
electromagnetic emission from plasma) otherwise absent in 
PTS. Under the same experimental conditions, the cytotoxicity 
of direct treatment is sometimes stronger than indirect treatment 
[36], [37]. Direct LTP treatment is also suggested to produce 
additional cellular effects like endogenous H2O2 generation by 
cells [38]–[41] and sensitization of cancer cells to the 
cytotoxicity of long-lived reactive plasma species such as H2O2 
and NO2- [42], contributing to the uniqueness of LTP. Physical 
plasma factors alone can also sensitize cancer cells to the 
cytotoxic action of ROS, as seen for nanosecond-pulsed 




magnetic fields against B16F10 melanoma cells [41] and pulsed 
electric fields against leukemia cells [42]. A recent study 
demonstrated that glioblastoma cell lines U87MG and A172 
could be sensitized to cytotoxicity of temozolomide (TMZ), a 
drug used for treatment of brain tumors, by the electromagnetic 
emission from a helium-discharged tube [43]. Vice versa, drug-
sensitized melanoma cells have been shown to be more 
susceptible to plasma-induced cell death [44]. 
Direct LTP treatment has already been widely used in many 
animal studies. Direct plasma treatment on the skin above a 
subcutaneous glioblastoma U87MG xenograft tumor site in 
mice reduced tumor size and prolonged their life [45]. 
Fractionated treatment was demonstrated to have improved 
anti-tumor effect compared to a single, longer treatment [46]. 
Similar anti-tumor effects after direct plasma treatment of 
subcutaneous tumors of different origins, including melanoma, 
bladder cancer, pancreatic carcinoma, breast cancer, head and 
neck cancer, and neuroblastoma in animal models have been 
reported [47]–[50].  
 
VII.2 Challenges and Proposed Solutions 
A key challenge in the use of LTP for treatment of cancers is 
the identification of its mechanism of action. The contribution 
of individual plasma components to its antitumor effects 
remains largely unknown. While most of the research describes 
the cause-and-effect relationship between chemical species and 
tumor toxicity, it is still unclear how much the physical factors 
of LTP contribute to the cellular responses observed. An 
important, practical consideration to keep in mind is that when 
cancer cells or tissues are directly exposed to LTP, they 
experience both physical and chemical effectors simultaneously 
and as such, the observed biological response could be 
attributed to the synergistic effect of the physical and chemical 
factors. In vitro, these effects are difficult to study because 
liquid layers of dozen of micrometers block physical factors and 
only allow chemical factors such as reactive species to affect 
cells. An initial attempt was recently published where cells 
were treated from the bottom of an inverted multi-well plate or 
cell culture dish to block all factors except electric fields [51]. 
This in vitro treatment caused necrotic killing effect on at least 
six cancer cell lines, including cell lines that are resistant to 
reactive species [52], [53]. In vivo, necrosis may trigger an 
immune response or an inflammatory response [54]. where 
physical factors in LTP are very relevant in direct treatment 
strategies. Furthermore, based on the results of a recent study, 
the effects of microwave emission from a plasma was 
determined to have decontamination efficacy [55]. This trans-
barrier capacity of LTP treatment suggests the non-invasive 
potential in medical application but more extensive studies are 
needed to understand the mechanism of interaction of 
physically-based modalities with cells and tissues. 
The second challenge is the insufficient understanding of the 
biological impact of LTP on tissues, a prerequisite to explore 
the underlying mechanism of LTP-based anti-cancer effects. 
Besides the well-accepted direct cytotoxic effects of LTP on 
cancer cells, evidence is now accumulating to show that it 
triggers unique immune responses and immunogenic cell death 
in vivo, providing clues to help understand LTP effects at the 
tissue level. Immunogenic cancer cell death (ICD) is elicited in 
response to various stimuli [56]. Sterile inflammation via 
damage-associated molecular patterns (DAMPs) overrides the 
immunosuppressive properties associated with apoptosis, 
which drives dendritic cell (DC) maturation and anti-tumor T 
cell responses [57]. The importance of immunity [58], 
immunogenicity and antigen presentation [58], ICD [59], and 
vaccination [60], [61] for plasma cancer treatment has been 
extensively reviewed recently. Increased immunogenicity has 
been described in several in vitro studies [62]–[69], and a 
number of reports suggest an enhancement of anti-tumor 
immune function following plasma cancer treatment in vivo 
[70]–[73]. The mechanism proposed is that plasma-induced 
oxidative stress elicits ICD, albeit direct in vivo evidence, e.g., 
via systemically enhanced antioxidants or tumor cell clonotypes 
with enhanced expression of antioxidant enzymes to scavenge 
ROS/RNS and thus inhibit (immunogenic) cell death, is 
lacking. From recent in vitro data, it can be concluded that the 
role of antioxidant defense molecules such as catalase is less 
pronounced in terms of plasma-induced cell death induction 
[74]. In vitro, several studies have suggested activation of 
professional antigen-presenting cells (APCs), myeloid cells 
critical in providing T cell co-stimulation and activation, 
following plasma treatment or following exposure to plasma-
treated tumor cells [75]–[80]. A new research field and 
potential therapeutic approach has been recently opened up by 
investigating the immunogenicity of proteins, showing that 
plasma-treated chicken ovalbumin, a model protein, provided 
enhanced protein immuno-recognition in vitro and tumor 
growth reduction in vivo [75]. The implications of these 
findings for tumor vaccination and therapeutics are vast and 
provide a basis for further investigation [61]. 
The ultimate goal of plasma oncotherapy is its translation for 
clinical application and it remains an important topic for 
continued exploration and discussion among experts in the 
multiple disciplines that contribute to exciting new 
developments in plasma medicine. Based on the different ways 
by which tumor tissue may be exposed to LTP, as decribed 
above, it is quite clear that it offers great flexibility in different 
cancer scenarios. Here we propose our vision for how LTP may 
be used for cancer therapy. 
For the more accessible tumors, like those that are 
subcutaneous, a direct, fractionated treatment with few to 
several treatment cycles over the skin of the tumor site would 
be easy and practical. Preliminary reports using the kINPen 
MED plasma jet in patients suffering from metastatic 
melanoma was however unsuccessful, perhaps because of the 
thickness of the skin. In contrast, treatment of ulcerating, 
locally advanced squamous cell carcinoma of the oropharynx 
[4] inhibited the growth of tumors in some patients. Incisional 
biopsies found apoptotic tumor cells and a desmoplastic 
reaction of connective tissue. In another clinical application, 
LTP was used to treat oral premalignant lesions (leukoplakia) 
[81]. Side effects were mild, not life-threatening, and transient 
with no long-term after effects [82]. Improved understanding of 
the mechanism of LTP action could help improve clinical 
treatment guidelines for better efficacy. In the case of deep 
tumors like intraperitoneal carcinomatosis, while topical LTP 
treatment is not possible, PTL offers a convenient solution via 
subcutaneous or intraperitoneal injections. The sensitization of 
cancer cells to the cytotoxicity of drugs provides the added 




benefit of a third option of synergy with LTP, as previously 
suggested in in vitro and translational models using the 
guideline-based drugs gemcitabine and cisplatin [83]. This 
LTP-induced selective sensitization of cancer cells is another 
new direction for further investigations: not aim to kill cancer 
cells but to sensitize cancer cells to traditional chemotherapy by 
chemical or physical factors as well as their combinations. 
LTP may be also be used as an adjunct therapy to standard of 
care surgery by treating exposed tumor tissues or the remnants 
of tumor tissue during surgery. In a minimally invasive surgical 
approach, LTP can be used with endoscopic plasma technology 
to treat deep tumor tissues [84]. 
LTP as an adjunct therapy was tested clinically for the first time 
in a patient with stage 4 colon cancer at Baton Rouge General 
Medical Center in Baton Rouge, Louisiana, immediately after 
surgery to remove the tumor [1]. Phase I safety clinical trial was 
completed in 2021 that involved 20 patients to evaluate the 
safety of the procedure [85].  
An important consideration for translation is the precise and 
controlled delivery of plasma effectors. The chemical 
composition, physical emission, and other parameters of LTP 
can be quickly modulated for specific needs [86]–[90]. To this 
end, an intelligent LTP system should scan the cellular 
responses to LTP and modify discharge conditions in real-time 
via feedback mechanism based on machine learning [91]. A 
real-time control of LTP is capable of optimizing the killing 
effect on cancer cells or tissues while protecting normal cells or 
tissues [92]. Such an intelligent LTP system is proposed as the 
self-adaptive LTP source, which may guide the design of the 
next generation of LTP sources [93]. To build an adaptive LTP 
system, a multi-parametric control system is necessary. The 
feedback control algorithm may use nonlinear model-predictive 
controls (MPC), a strategy used to implement a numerical 
solution of an open-loop optimization in feedback [94], [95]. 
The adaptive plasma approach may ultimately realize a 
personalized LTP-based cancer therapeutic that could be 
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VIII. MODELING OF LTP-CELL AND LTP-TISSUE 
INTERACTIONS 
A. Bogaerts* and M. Yusupov 
VIII.1 Current State 
For improving plasma medicine applications, a good insight 
is needed in the interactions of LTP with cells and tissues. This 
can be obtained by modeling, as it can provide detailed 
information, even on the molecular level, which might 
experimentally be less (or not) accessible. Below, we make a 
distinction between modeling the interaction of LTP with (i) 
entire cells or tissue, and (ii) individual cell components, 
because they require quite different modeling approaches. 
 
Modeling the interaction of LTP with entire cells or tissue:  
The interaction of LTP with entire cells or tissue can up to 
now only be simulated on a macroscopic scale. As a result, the 
information is less detailed, but it can give an approximate view 
on the effect of e.g., electric fields induced by plasma streamers 
on tissue, as demonstrated by Babaeva and Kushner [1] for a 
DBD plasma interacting with wounded skin. The actual skin 
tissue was mimicked by a cellular structure in the model. In 
collaboration with Ning and Graves, the authors also calculated 
the ion energy and angular distributions incident on cell 
membranes, and applied molecular dynamics (MD) simulations 
of ion sputter probabilities of typical lipid-like material [2]. In 
some follow-up papers (e.g., [3, 4]), Babaeva, Tian, Lietz and 
Kushner extended their model to wounded skin covered by 
liquid, containing also blood platelets. The major focus was on 
the plasma-liquid model, but some description was also given 
on the electric fields delivered to the blood platelets and cells 
[3], and on the interaction of the DBD treating liquid-covered 
tissue [4]. Likewise, Kong and coworkers [5] developed a semi-
1D model for plasma-biofilm interaction and plasma-tissue 
interaction, based on a reactive penetration model for mass 
transfer of plasma species across the gas-liquid boundary. 
  
Modeling the interaction of LTP with individual cell 
components:  
Modeling LTP interactions with individual cell components 
is possible on the molecular level, and much progress has been 
made in recent years. Depending on the system size and level 
of detail, different modeling approaches can be used, ranging 
from quantum mechanics (QM), over density functional theory 
(DFT) and density functional tight binding (DFTB), to classical 
molecular dynamics (MD); see [6] for a detailed description. 
DFT (and other QM methods with higher accuracy) are 
typically too time-consuming for describing realistic model 
systems of interest for plasma medicine, but DFTB has been 
applied, e.g., to study the interaction of ROS with the head 
group of the PLB [7]. Among the classical MD methods, we 
distinguish reactive and non-reactive MD simulations. Reactive 
MD allows the breaking and formation of bonds, and thus the 
description of chemical reactions between plasma species and 
biomolecules, as illustrated, e.g., for the interaction of ROS 
with peptidoglycan [8] (of interest for bacteria killing), with 
lipids [2] and DNA [9]. Non-reactive MD, also called 
“molecular mechanics” (MM), does not consider bond breaking 
and formation, but it allows to describe large systems and over 
longer time scales, e.g., for the transport of species through a 
PLB or the structural deformation and stability of biomolecules. 
This method has become increasingly attractive in plasma 
medicine, and some examples will be presented in next 
sections.  
 
(a) Modeling LTP interaction with the phospholipid bilayer 
(PLB):  
When RONS produced by LTP come in contact with cells, 
they first “see” the cell membrane, composed of a PLB with 
proteins embedded. It is of great interest to study the 
permeability of RONS through the PLB. It can provide 
information on RONS distribution, mobility and residence 
times at the membrane-water interface, as well as their 
translocation free energy barriers across the PLB, showing 
whether they can easily reach the cell interior. For instance, 
Cordeiro [10] studied the transport properties of ROS (i.e., OH, 
HO2, H2O2 and O2) across the PLB, employing non-reactive 




MD simulations. He found that hydrophobic O2 is able to 
accumulate at the PLB interior, whereas hydrophilic OH, HO2 
and H2O2 mainly stay around the lipid head groups [10].  
Furthermore, the PLB can also be oxidized by LTP, and 
therefore, simulations have been performed to compare the 
RONS permeability through both native and oxidized PLBs 
[11]. Figure VIII.1 illustrates the free energy profiles (FEPs), 
obtained from so-called umbrella sampling (US) non-reactive 
MD simulations, of various RONS across both native and 50% 
oxidized PLBs. The FEP of hydrophilic ROS (i.e., OH, HO2, 
H2O2) shows a minimum around the head groups, followed by 
a steep rise towards the center, thus creating a clear energy 
barrier to cross the PLB. These results are similar to those 
mentioned above [10]. Upon oxidation, the hydrophilicity of 
the PLB rises, resulting in a larger permeability for hydrophilic 
ROS, as demonstrated by the much lower free energy barrier in 
Figure VIII.1(b). 
 
Fig VIII.1 Free energy profiles (FEPs) of the hydrophilic (a-b) 
and hydrophobic (c-d) RONS, across native (a,c) and 50% 
oxidized (b,d) PLBs. The average positions of the head group 
regions (i.e. phosphate atoms of the PLB) are indicated by light 
blue color. 
 
Because the hydrophilic ROS prefer to reside close to the 
head groups, DFTB simulations were performed to study 
oxidation of these head groups [7]. HO2 and H2O2 were found 
not to chemically react with the head groups, while OH radicals 
cause detachment of some parts in the lipids, enhancing the 
membrane fluidity and reducing the lipid order. This may allow 
RONS to penetrate more easily through the PLB, causing 
further lipid tail (per)oxidation, which might result in pore 
formation (see further).  
The hydrophobic RONS (e.g., O2, O3, NO, NO2 and N2O4) 
exhibit very low permeation barriers around the PLB head 
groups and minima in the center; see Figure 1(c,d). Hence, they 
can cause lipid (per)oxidation in the lipid tail region. Upon 
oxidation, the PLB can become a bit more fluidic, making the 
FEPs of the hydrophobic RONS a bit smoother, but otherwise 
they do not change significantly. These simulations correlate 
well with experiments, where the permeability of hydrophobic 
RONS (NO and O2) was found to be 3-6 orders of magnitude 
higher than for H2O2 [12]. Thus, hydrophobic RONS may easily 
permeate through the cell membrane, while the active transport 
of hydrophilic ROS in and out of the cell should only be 
possible in the presence of aquaporin (AQP) channels or pores. 
US simulations [13] indeed predicted a 100 times higher 
permeability through AQP than through the PLB, which might 
explain the selectivity of LTP towards cancer cells, because 
cancer cells typically have a higher AQP expression in their cell 
membrane. In addition, pore formation in the cell membrane 
after lipid (per)oxidation has also been studied by non-reactive 
MD [14], as well as the combined effect of lipid oxidation and 
an electric field [15].  
Besides the higher expression of AQP, some cancer cells also 
have a lower cholesterol content in their cell membrane than 
normal cells. MD simulations [16] revealed higher free energy 
barriers for hydrophilic ROS at higher cholesterol contents, 
making it more difficult for them to penetrate through the cell 
membrane. Furthermore, the FEP of O2 showed new free 
energy barriers close to the sterol rings, which will limit the 
probability of lipid (per)oxidation of the lipid tails, and hence 
pore formation. Finally, MD simulations also predicted the 
absence of pore formation for cholesterol fractions above 15 % 
[14]. Hence, RONS should be able to penetrate more easily 
through the membrane of cells with lower cholesterol fraction, 
such as cancer cells, resulting in oxidative stress inside the cell, 
while this effect might not happen in normal cells, due to their 
higher cholesterol fraction. This might provide another 
explanation for the selective anti-cancer effect of LTP.  
 
(b) Modeling LTP interaction with DNA :  
Reactive MD simulations revealed two main types of 
reactions of OH radicals with a DNA model system, i.e., H-
abstraction and (ii) OH-addition [9]. The H-abstractions create 
a radical, resulting in even more (intermolecular) H-
abstractions, possibly leading to single strand breaks (SSBs). 
Combined with a second SSB at the opposite strand in close 
vicinity, this may lead to a double strand break (DSB). The 
latter could however not be observed in these MD simulations, 
because of their limited time scale (see also section 2). The OH-
addition on the purine ring of the nucleic bases, more 
specifically at the C-8’ position of dAMP and dGMP, yielded 
8-hydroxy-purine adduct radicals (8-OH-Ade• or 8-OH-Gua•), 
which is the first step towards 8-oxo-guanine (8-O-Gua) and 
2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapydG) 
formation, i.e., markers for oxidative stress in cells. The latter 
may affect biochemical pathways within the affected cell, e.g., 
introduction of DNA mutations or inhibition of gene 
expressions, possibly leading to apoptosis, but again, the 
simulated time was not long enough to observe these further 
reactions, due to the high computational cost of the simulations. 
 
(c) Modeling LTP interaction with proteins :  
Non-reactive MD, molecular docking and US (binding free 
energy) calculations investigated the structural conformation 
and binding affinity of human epidermal growth factor (hEGF; 
one of the important signaling proteins in both wound healing 
and cancer treatment) to its receptor (hEGFR) under oxidative 
stress as induced by LTP [17]. Mild oxidation was found to not 
significantly affect this binding affinity, and will thus not 
strongly influence cell signaling pathways, and hence cell 
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times are beneficial for chronic wound healing. On the other 
hand, the interaction was clearly reduced upon stronger 
oxidation, which might disturb the cell signaling pathways, 
ultimately leading to disruption of cell proliferation. This may 
explain why longer plasma treatment times result in inhibiting 
cancer cell proliferation and even cancer cell death [17]. 
In general, the effects of post-translational modifications 
(e.g., methylation, phosphorylation, glycosylation and 
acetylation) on various protein structures have been widely 
studied in literature, but it would also be interesting to study in 
more detail the effects of oxidation by ROS (and nitrosylation 
by RNS), on the protein stability and its binding affinity, 
specifically in the context of LTP for cancer treatment, which 
is till now only scarcely investigated. Indeed, such studies 
would help to further unravel the molecular level mechanisms 
of cancer cell death induced upon oxidation by LTP. 
 
VIII.2 Challenges and Proposed Solutions 
 
Compromise between level of detail and calculation time: 
The major challenge in modeling LTP interactions with cells 
or tissues is the compromise between calculation time and level 
of detail of the simulations. Macroscopic modeling is fast, but 
can only provide a general, approximate picture. Molecular-
level modeling yields detailed information, but the small time 
step needed makes these simulations limited to small system 
sizes and time scales. In addition, the complexity of cells or 
tissues makes it difficult to study the processes at the molecular 
level. Thus, important and specific parts of cells (e.g., the PLB 
or transmembrane proteins) are often chosen as model systems 
in molecular-level simulations in order to understand the 
underlying mechanisms of the LTP effect on cancer cells. 
Figure VIII.2 presents the time and length scales of the various 
molecular-level simulations, mentioned in the previous section.  
 
Fig. VIII.2 Overview of the various molecular-level modeling 
approaches for the interaction of reactive species (e.g., RONS) 
as produced by LTP, with biomolecules, or for the (longer-
term) effects of these interactions, illustrating the length and 
time scales that can be reached. QM = quantum mechanics, 
DFTB = density functional-tight binding, QM/MM = quantum 
mechanics / molecular mechanics, rMD = reactive molecular 
dynamics, nrMD = non-reactive molecular dynamics, uaMD = 
united-atom molecular dynamics, cgMD = coarse-grained 
molecular dynamics. The length and time ranges are 
approximate and improve over time with the increase of 
supercomputer capacities. Adopted from [6] with permission. 
 
The computational quantum mechanics (QM) methods, 
including DFT, are the most accurate, but for plasma medicine, 
only approximate DFT methods (e.g., DFTB) or classical 
reactive MD methods would be feasible, keeping in mind the 
required system sizes of relevant biomolecules. While DFT is 
more approximate than other QM methods, it is also still very 
time-consuming, and thus able to handle system sizes only in 
the order of 100 atoms for a simulation time ranging from a few 
days up to a few weeks (on e.g., a supercomputer node with 
dual 14-core Intel E5-2680v4 Broadwell generation CPUs 
connected through an EDR InfiniBand network). Note that the 
time range depends on which type of software (e.g., VASP or 
Gaussian) is employed and whether a simple geometry 
optimization or deeper characterization is carried out, as well as 
on the system size, i.e., finite (e.g., cluster) or infinite (i.e., 
system in a periodic box). DFT-based MD calculations, also 
called “ab initio MD” (AIMD) can handle time scales in the 
order of picoseconds. DFTB, on the other hand, can typically 
handle a few 1000 atoms on time scales of 10s of picoseconds, 
making it indeed more suitable for biomedical studies on 
relevant model systems. Classical reactive MD, in which the 
forces are not based on QM data but on classical fitting 
parameters, can handle much longer time scales (order of 1 ps 
to 100 ns) and larger systems (103-105 atoms), depending on the 
complexity of the force field (interaction potential), but of 
course, at the expense of the level of detail. Moreover, the 
accuracy critically depends on the chosen force fields. Because 
of the larger system sizes, it has been used more often in 
literature in the context of plasma medicine (see section 1.2). 
However, the simulation time scale is still very limited, and 
thus, many relevant biochemical processes are still beyond 
reach, as illustrated in section 1.2(b), for the interaction of LTP 
with DNA. Indeed, DSBs in DNA, and the reaction of 8-OH-
Ade• and 8-OH-Gua into 8-O-Gua and FapydG (i.e., markers 
for oxidative stress in cells), could not be observed within the 
time scale of the MD simulations. 
Non-reactive MD can handle much larger system sizes and 
time scales (typically two orders of magnitude) than reactive 
MD. So-called “all-atom force fields” (i.e., when all atoms in 
the system are treated separately), can describe in the order of 
105-107 atoms, at time scales of 0.1 ns – 10 s. So-called 
“united-atom force fields” treat all heavy atoms separately, 
while the H atoms bound to a C atom (e.g. in the apolar tails of 
phospholipids) are treated as one (methyl or methylene) group. 
Hence, this yields less separate particles in the system, allowing 
to simulate larger systems (typically up to one order of 
magnitude larger), for the same time scales. Finally, “coarse-
grained methods”, in which the atoms comprising entire 
functional groups (i.e., typically, 3-5 heavy atoms with their H 
atoms) are represented by so-called coarse-grained particles, 
further reduce the number of particles in the system, and thus 
allow even larger system sizes (or to speed up the calculations). 
This opens possibilities for describing larger biomedical 
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In general, there will always be a trade-off between 
calculation time and level of detail/accuracy. Thus, it can be 
interesting to combine the above methods, for a more 
comprehensive picture. For instance, Yusupov et al. [7] 
combined reactive (DFTB) MD (to study the interaction of ROS 
with the head groups of the PLB) with non-reactive (classical) 
MD (for the subsequent effect of head group and lipid tail 
oxidation on the structural and dynamic properties of the cell 
membrane).  
Furthermore, while the above example illustrates the use of 
two separate methods, it is also possible to combine different 
methods in an integrated simulation, in quantum mechanical / 
molecular mechanics (QM/MM) methods. A small (chemically 
most relevant) part of the system (e.g., the active site of the 
biological system) can be described at the quantum chemical 
(electronic) level, while the surrounding embedding atoms and 
molecules may be treated at a classical (atomic) level. This 
method can thus combine the strengths of different modeling 
approaches, and it would be very interesting to explore its 
potential in plasma medicine. Indeed, QM/MM is successfully 
used for many years in biochemistry, e.g., to describe the 
enzymatic reaction mechanisms (or catalytic properties) of 
various enzymes [18].  
Finally, it would be interesting to apply other enhanced 
sampling methods in the context of plasma medicine. These 
methods include US (see section 1.2(a)), metadynamics 
(MetaD), steered MD (SMD), replica exchange MD (REMD), 
and accelerated MD (aMD), which are successfully applied to 
a wide range of biological systems, to study conformational 
changes of proteins, protein-protein and protein-ligand 
interactions, enzyme catalysis, and so on [19]. Each of these 
approaches has its advantages and disadvantages from the 
computational and application perspective. For instance, US is 
very popular for free energy barrier calculations, because of its 
quick convergence and ability of simultaneously running 
multiple independent simulations (windows). However, the 
harmonic potentials used for US windows need to be tuned 
manually, to obtain reasonable positional overlaps between the 
windows along the collective variable (CV, e.g., bilayer 
normal). Moreover, adding further US windows to the system 
may be necessary to improve the convergence of the sampling. 
Lastly, US simulations are time consuming for large and 
complex systems. An advantage of MetaD is that a priori 
knowledge of the end states is not required, and several CVs 
can be used to explore possible pathways. However, the 
efficiency of MetaD does not scale well with the number of 
used CVs, and the accuracy and convergence depends on the 
choice of the necessary parameters [19]. When little is known 
about the events to be simulated (e.g., protein folding), REMD 
or aMD are probably the best methods. More information on 
these and other enhanced sampling and free energy calculation 
methods is given in [19]. 
 
The need for accurate input data: 
Another challenge, related to the first one, is the need for 
accurate input data in both macroscopic and molecular-level 
simulations. This certainly applies to the macroscopic 
simulations, which are based on many assumptions, but even 
for the most accurate molecular-level methods, the accuracy of 
the calculation results critically depends on the input data, e.g., 
the chosen functionals in DFT or the force fields in classical 
MD. Hence, there is a constant need for improved functionals 
and force fields, to further improve the predictive power of the 
calculations. Even more, the lack of some force fields is 
limiting the possibilities of MD to obtain an overall picture. For 
instance, the lack of accurate force field parameters of RNS 
(e.g., HNO2, HNO3, ONOOH) for reactive MD simulations 




Experimental validation is another big challenge, certainly 
for the molecular-level simulations. Indeed, due to small sizes 
of biomolecular systems, sophisticated experimental methods, 
such as neutron scattering, small-angle X-ray scattering 
(SAXS), nuclear magnetic resonance (NMR), cryogenic 
electron microscopy (cryo-EM), and electrospray ionization 
mass spectrometry (ESI-MS), would be needed. Furthermore, 
dedicated experiments should be designed, under very 
controlled conditions, generating for instance only a beam of 
OH radicals, instead of the cocktail of RONS produced by LTP. 
Moreover, experiments should be performed for well-defined 
model systems, as considered in the simulations, gradually 
mimicking more complex tissues. Such experiments are set up 
in various labs, for instance, for studying the separate and 
synergistic effects of plasma-generated radicals and UV/VUV 
photons at the cellular and molecular level for various kinds of 
biomolecules, or experiments with simple model systems for 
the cell membrane, based on synthetic phospholipid membrane 
vesicles or liposomal model membranes (e.g., [20-22]).  
For instance, in [7], the MD simulations were validated 
experimentally, using liposomes as model systems for the 
biological membranes. The so-called Laurdan Assay was used 
to determine the phase states of the membranes (gel- or liquid-
phase) by measuring the penetration of water molecules into the 
bilayer, which strongly correlates with the packing of the 
phospholipids. In addition, high resolution mass spectrometry 
was applied for studying modifications of the liposomes after 
LTP treatment. The experiments revealed a slight initial rise in 
membrane rigidity, followed by a strong and persistent increase 
in fluidity (indicating a drop in lipid order) upon LTP treatment, 
in good agreement with the simulations. Besides, also indirect 
validation, by means of biological assays, can be very useful, 
and a few examples are presented in the next section. 
  
Translating the insights for improving biomedical applications: 
Finally, while the molecular-level simulations provide 
detailed insights in e.g., how RONS can penetrate through the 
cell membrane, either by passive transport (for hydrophobic 
RONS) or through pores or AQP channels (for hydrophilic 
RONS), the long computation time dictates the use of simple 
model systems (e.g., a simple PLB and/or AQP), while the cell 
membrane contains many other lipids and proteins as well, such 
as antiporters, catalase, etc. Indeed, the reality in plasma 
medicine is much more complicated, and it is not 
straightforward to translate the insights obtained from these 
simple model systems to the real world, and thus to actually 
improve the biomedical applications. For instance, taking the 
same example of the cell membrane, the various RONS might 
create a myriad of different lipid oxidation (and nitration) 




products, which are not yet accounted for in these simulations. 
Hence, more knowledge is crucial on the different products 
formed, and how they affect the biophysical properties and 
function of the cell membrane. Furthermore, lipid peroxidation 
might lead to liquid ordered-liquid disordered phase separation 
in membranes [23], and this might favor pore formation. Thus, 
it would be interesting to account for phase-separated 
membranes (or lipid rafts) as well, as they can play a crucial 
role in cell permeability. Specifically, the interface region 
between these rafts (e.g., gel and fluid domains), the thickness 
mismatch between both phases, the membrane elasticity and the 
lipid packing, all together can affect the membrane permeability 
[24]. 
Likewise, studies on LTP-induced oxidation of certain 
proteins (e.g., hEGF; see section 1.2(c)) typically account for 
only some effects, but in reality, many more proteins play a role 
in plasma medicine. Specifically, for plasma cancer 
immunotherapy, it would be important to investigate the 
interaction between immune cell proteins and cancer cell 
proteins, under native conditions and oxidative stress (as 
induced by LTP). Protein-protein interactions have indeed been 
computationally studied in many different fields (e.g., [25]). 
While the effect of mutations in proteins and drugs that block 
the binding of immune checkpoint proteins to receptors has 
been simulated (e.g., [26]), the interaction between immune cell 
and cancer cell proteins under oxidative stress, as induced by 
LTP, has only been the subject of one recent study [27] (see also 
next paragraph), showing the need for such type of modeling, 
for a better insight in plasma cancer immunotherapy. 
In general, however, molecular-level simulations certainly 
contribute to a better understanding in plasma medicine, and 
there are some recent examples in literature on the combined in 
silico, in vitro and even in vivo studies for the effect of LTP on 
specific biomolecules, where simulations did provide a better 
understanding of the experiments. For instance, Lin et al. [27] 
performed a combined in silico, in vitro (with 3D tumor 
models) and in vivo study on the effect of LTP on CD47 (a key 
innate immune checkpoint, which was found to be modulated 
after LTP treatment). Simulations revealed that the potential 
oxidized salt-bridges are responsible for conformational 
changes. US simulations of CD47 demonstrated that oxidation-
induced conformational changes reduce its binding affinity with 
its receptor (signal-regulatory protein alpha; SIRPα), thus 
providing new insight into the potential of LTP for cancer 
immunotherapy, i.e., for reducing immunosuppressive signals 
on the surface of cancer cells. Also, Shaw et al. [28] used MD 
simulations to support in vitro and in ovo experiments on the 
synergistic cytotoxic effect of PTL with melittin (a small 
peptide component of bee venom, with reported anti-cancer 
effects in vitro and in vivo). Indeed, the simulations revealed 
that LTP-induced oxidation of the PLB results in a lower energy 
barrier for translocation of melittin compared to the non-
oxidized PLB. Likewise, in [29] the molecular effect of LTP-
induced oxidative stress on the interaction between CD44 and 
hyaluronan (HA) was investigated. Multi-level atomistic 
simulations revealed a drop in the binding free energy of HA to 
CD44 upon oxidation, supporting the experimental results, and 
the hypothesis that LTP-induced oxidation disturbs the CD44–
HA interaction, which can inhibit proliferative signaling 
pathways inside tumor cells, and induce cancer cell death. 
Finally, besides the molecular-level simulations, it would be of 
great interest to study cell signaling pathways, which might also 
explain the selectivity of plasma for cancer therapy [30]. 
Indeed, experiments indicated that two apoptosis-inducing 
signaling pathways, that are both inhibited by catalase in the 
extracellular compartment, could be reactivated upon 
inactivation of catalase in the cell membrane of cancer cells. If 
LTP could inactivate catalase, it may induce cancer cell death 
upon reactivating these signaling pathways. It is clear that a 
better understanding of this apoptosis-inducing mechanism and 
the role of catalase inactivation would be of great value. Such 
mechanisms can obviously not be simulated by molecular-level 
simulations, and macroscopic reaction kinetics modeling would 
be needed to study the mechanisms of the cell’s antioxidant 
defense system and redox signaling, as extensively used in the 
field of redox biology (e.g., [31]). Developing such models is 
very challenging, and would have to be done step-by-step, 
starting with simple model systems, and gradually adding 
complexity. This has recently been demonstrated by Bengtson 
and Bogaerts, who developed a mathematical model to study 
the role of catalase inactivation for reactivating the two above-
mentioned apoptotic signaling pathways, trying to understand 
the underlying cause of the anti-cancer effect of LTP [32]. In 
addition, they also developed another model to describe the key 
species and features of the cellular response, in an attempt to 
quantify the (possible) selective and synergistic anti-cancer 
effects of PTL. The latter model investigated the cell 
susceptibility towards exogenous H2O2 (alone and in 
combination with NO2-), in terms of two variables, i.e., the 
H2O2 membrane diffusion rate constant and the intracellular 
catalase concentration, and predicted that the maximum 
intracellular H2O2 concentration could be used to quantify the 
cell susceptibility towards exogenous H2O2 [33]. However, 
clearly more modeling efforts in this field are needed, to gain 
further insight in the underlying mechanisms of the (selective) 
anti-cancer action of LTP. 
In general, it is clear that much more research will be needed 
to elucidate all the underlying mechanisms of LTP for 
biomedical applications. However, this section showed that 
computer simulations can definitely contribute to elucidate 
some pieces of the puzzle. 
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IX. CONCLUDING REMARKS 
 
On the fundamental scientific level, the advent of the 
application of low temperature plasma in biology and medicine 
has allowed for the creation of new scientific knowledge 
regarding the interaction of the 4th state of matter with soft 
matter, such as biological cells and tissues. Twenty-five years 
ago, such knowledge was simply missing. For decades plasma 
technology has been playing a major role in several industries 
that serve our modern society, but its introduction to the 
biomedical field is comparatively recent. Nonetheless, the 
potential socio-economic impact of using atmospheric pressure 




low temperature plasma to overcome outstanding hygiene, 
safety, and medical challenges cannot be overstated. As shown 
in this paper, LTP is today a well-established and accepted 
technology that is helping solve many serious issues related to 
public health, food and water safety, and others. However, to 
push the field to a higher level of maturity, more fundamental 
scientific work and novel advanced application concepts are 
still needed. To help facilitate this process, the team of experts 
who contributed to this roadmap paper have proposed viable 
ideas and potential approaches that should carry the field 
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